Page last updated: 2024-08-23

paclitaxel and Cancer of Endometrium

paclitaxel has been researched along with Cancer of Endometrium in 337 studies

Research

Studies (337)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	20 (5.93)	18.2507
2000's	100 (29.67)	29.6817
2010's	161 (47.77)	24.3611
2020's	56 (16.62)	2.80

Authors

Authors	Studies
Bao, S; Cai, J; Peng, S	1
DiSilvestro, PA; Filiaci, VL; Fowler, JM; Huang, HQ; Matei, D; Matulonis, UA; Miller, DS; Moxley, KM; Mutch, DG; Nakayama, JM; Powell, MA; Randall, M; Richards, WE; Spirtos, NM; Tewari, KS; Wenzel, LB	1
Egawa-Takata, T; Enomoto, T; Fujiwara, H; Honma, S; Hori, K; Ito, K; Kikuchi, A; Kimura, T; Koji, N; Nagasawa, T; Nishio, S; Nishio, Y; Oishi, T; Okamoto, A; Shimada, M; Tadahiro, S; Takei, Y; Tanabe, H; Ueda, Y; Ushijima, K; Yamada, T	1
Bao, S; Cai, J; Jin, Y; Wu, D	1
Maeoka, Y; Nakanishi, K; Suzuki, S; Yamada, T	1
Guo, H; Li, D; Li, W; Liu, N; Pan, G; Sheng, X; Wang, C; Yuan, L	1
Blachut, B; Bruce, SF; Cho, K; Fuh, KC; Hagemann, AR; Khabele, D; Kuroki, LM; Lomonosova, E; McCourt, CK; Mullen, MM; Mutch, DG; Noia, H; Oplt, A; Patti, GJ; Powell, MA; Shriver, LP; Stock, EC; Thaker, PH	1
Camejo, HS; Heffernan, K; Knott, C; Nikitas, FS; Shukla, U	1
Chen, JR; Hung, SM	1
Bayascas, JR; Bolinaga-Ayala, I; Colas, E; Diéguez-Martínez, N; Dolcet, X; Domingo-Ortí, I; Espinosa-Gil, S; Gorgisen, G; Lizcano, JM; Megías-Roda, E; Pérez-Montoyo, H; Viñas-Casas, M; Yoldi, G	1
Hu, Y; Li, J; Shao, X; Wei, Q; Zhang, Z	1
Crane, E	1
He, D; Li, L; Qu, X; Wang, Y	1
Aoki, D; Makker, V; Monk, BJ; Nogueira-Rodrigues, A; Rubinstein, M; Sehouli, J; Shen, S; Tan, DSP	1
Chen, JL; Gao, FF; Liu, NF; Sui, XC; Tang, YD; Zhang, TT; Zhang, XL	1
Barber, EL; Chen, S; Hill, EK; Kocherginsky, M; Matei, D; O'Shea, KL; Pineda, MJ; Robertson, SE; Schilder, J; Teoh, D; Zhang, B	1
Cai, H; Chen, J; Deng, P; Guan, T; Hu, J; Huang, S; Li, H; Li, Y; Lin, Y; Liu, M; Song, T; Zeng, H	1
Aoki, D; Nakanishi, T; Saito, T; Sugiyama, T; Takano, M; Takehara, K; Ushijima, K; Watanabe, Y; Yaegashi, N	1
Abuo-Rahma, GEA; Alhaj-Suliman, SO; Ebeid, K; Meng, X; Mohammed, HH; Naguib, YW; Saha, S; Salem, AK; Wafa, EI; Yang, S	1
Aghajanian, C; Al Baghdadi, T; Backes, F; Beffa, L; Cantuaria, GH; Eskander, RN; Fader, AN; Gien, LT; Girda, E; Hill, EK; Hinchcliff, EM; Hope, JM; John, VS; Kavecansky, J; Landrum, LM; Leath, CA; Lele, SB; Mannel, R; Mathews, C; Moore, RG; Musa, FB; O'Cearbhaill, RE; Powell, MA; Shahin, MS; Sill, MW; Thaker, PH; Welch, S	1
Auranen, A; Black, D; Boere, I; Buscema, J; Chase, DM; Cibula, D; Coleman, RL; Copeland, LJ; dePont Christensen, R; Gilbert, L; Gill, SE; Gold, MA; Hanker, LC; He, Z; Herzog, TJ; Landrum, LM; McCourt, C; Mirza, MR; Monk, BJ; Novák, Z; Pothuri, B; Powell, MA; Raspagliesi, F; Shahin, MS; Sharma, S; Slomovitz, BM; Stevens, S; Stuckey, A; Tian, M; Valabrega, G; Zografos, E	1
Arend, R; Barroilhet, LM; Birrer, M; Bradley, W; Castro, C; Dholakia, J; Duska, LR; ElNaggar, AC; Goodman, HM; Hamilton, E; Jackson, CG; Kagey, MH; Liu, A; LyBarger, K; Mahdi, H; Matulonis, U; O'Malley, DM; Piper, D; Sachdev, J; Sirard, CA	1
Andreetta, C; Arenare, L; Califano, D; Casanova, C; Cecere, SC; Chiodini, P; Cinieri, S; De Angelis, C; De Cecio, R; De Giorgi, U; Di Napoli, M; Farolfi, A; Gargiulo, P; Greco, F; Lombardi, D; Lorusso, D; Mammoliti, S; Perrone, F; Pignata, S; Pisano, C; Priolo, D; Rosati, M; Russo, D; Salutari, V; Scalone, S; Scambia, G; Schettino, C; Schiavetto, I; Spina, A; Zafarana, E	1
Bijlsma, RM; Franken, MD; Röckmann-Helmbach, H	1
Cho, HY; Jeong, SY; Kim, HS; Kim, JH; Kim, NH; Kim, Y; Lee, JJ; Lee, KJ; Park, ST	1
Fan, L; Liu, Y; Wang, C; Zhan, P	1
Bae-Jump, VL; Buckingham, L; Deng, B; Fan, Y; Hao, T; John, C; O'Donnell, J; Secord, AA; Shen, X; Sun, W; Suo, H; Zhang, X; Zhao, Z; Zhou, C	1
Allard, J; Bellina, M; Bernet, A; Blanpain, C; Braissand, N; Cassier, PA; Dalban, C; Decaestecker, C; Degletagne, C; Delord, JP; Devouassoux-Shisheboran, M; Dolcet, X; Ducarouge, B; Fattet, L; Gadot, N; Garin, G; Gheit, H; Hernandez-Vargas, H; Jelin, R; Lengrand, J; Léon, S; Matias-Guiu, X; Mehlen, P; Mery-Lamarche, E; Navaridas, R; Neves, D; Paradisi, A; Pastushenko, I; Perol, D; Rama, N; Ray-Coquard, I; Salmon, I; Zindy, E	1
Alexandre, J; Angelergues, A; Ferron, G; Frenel, JS; Gaillard, AL; Joly, F; Le Frère-Belda, MA; Lortholary, A; Ray-Coquard, I; Rouleau, E; Treilleux, I; You, B	1
Jiang, J; Mao, P; Wang, J; Wang, X; Zhang, C; Zhu, Y	1
Cavalcanti Souza, ME; de Almeida, AM; de Moraes, FCA; de Oliveira Rodrigues, ALS; Dos Santos, NPC; Fernandes, MR; Lopes, LM; Pasqualotto, E; Stecca, C	1
Enomoto, T; Ishiguro, T; Minamino, T; Mori, Y; Ohata, H; Okamoto, K; Sato, A; Ueda, H; Yamawaki, K; Yoshida, Y; Yoshihara, K	1
Aoki, D; Arai, M; Mizuno, M; Nakai, H; Nakanishi, T; Nishio, S; Nomura, H; Susumu, N; Takehara, K; Tokunaga, H; Watanabe, Y; Yaegashi, N; Yokoyama, Y	1
Guo, JL; Li, JH; Quan, Y; Tang, T; Yang, YH; Zhang, L	1
Breda, E; Cecere, SC; Cinieri, S; Colombo, N; Conte, C; Ferrandina, G; Lapresa, MT; Lombardi, D; Lorusso, D; Maltese, G; Pietragalla, A; Pignata, S; Pisano, C; Sabatucci, I; Sabbatini, R; Savarese, A; Scambia, G; Sonetto, C; Tagliaferri, P	1
Marnitz, S; Waltar, T	1
Bárdos, N; Bohonyi, N; Csima, M; Gőcze, P; Kalincsák, J; Koppán, M; Kovács, K; Papp, S; Toller, GL	1
Bloomfield, V; Helpman, L; Kazerouni, H; McGinnis, JM	1
Asano, H; Ihira, K; Kato, T; Kobayashi, N; Konno, Y; Kudo, M; Mayama, M; Mitamura, T; Nomura, E; Nozaki, A; Takeda, M; Watari, H	1
Liu, Q; Liu, W; Lu, W; Ruan, X; Zhang, X; Zheng, Y; Zhong, M	1
Abdelkhalek, S; Abdelmoety, D; Aboelnaga, E; Baraka, R; Elemam, O; Zeeneldine, A	1
Abdelghany, O; Azodi, M; Backes, FJ; Bellone, S; Buza, N; Celano, P; Chambers, S; Edraki, B; ElSahwi, K; Fader, AN; Havrilesky, L; Hui, P; Litkouhi, B; Lowery, W; Nevadunsky, N; O'Malley, DM; Pikaart, D; Ratner, E; Roque, DM; Santin, AD; Schwartz, PE; Secord, AA; Siegel, E; Silasi, DA	1
Areepium, N; Liblab, S; Vusuratana, A	1
Ishibashi, M; Nagase, S; Sakurada, S; Sato, I; Shigeta, S; Shimada, M; Tokunaga, H; Watanabe, Y; Yaegashi, N	1
Cross, V; Dircksen, C; Felten, A; Hahn, S; Johnson, T; Klein, P; Leamon, CP; Lu, J; Nelson, M; Parham, G; Pugh, M; Qi, L; Reddy, JA; Santhapuram, HK; Vaughn, JF; Vetzel, M; Vlahov, IR; Wang, K; Westrick, E	1
He, R; He, Y; Shao, K; Shi, Y; Wei, B; Yang, Y; Zhan, L	1
Krell, J; Lythgoe, MP; McNeish, IA; Tookman, L	1
Aoki, D; Banno, K; Yanokura, M	1
Collins, A; Hew, R; MacFarlane, M; Miles, GJ; Moss, EL; Powley, IR; Pringle, JH; Pritchard, C	1
Kim, JH; Lee, JH; Lee, KH	1
Aghajanian, C; Casablanca, Y; Cosgrove, C; Devor, EJ; Dewdney, S; Filiaci, VL; Jackson, A; Lankes, H; Leslie, KK; Levine, DA; Mallen, AR; Mathews, C; McDonald, ME; McHale, M; Moxley, K; Mutch, D; Richardson, D; Rose, PG; Secord, AA; Tewari, KS; Thiel, KW; Zhou, X	1
Bischoff, F; Bodurka, D; Coleman, RL; Fellman, BM; Garcia, ME; Hu, W; Meyer, LA; Nick, A; Palancia, J; Ram, P; Ramirez, PT; Schmeler, K; Soliman, P; Sood, AK; Westin, SN; Yuan, Y; Zhu, Z	1
Chen, Y; He, Y; Tang, N; Tang, Y; Xing, J; Zhao, N	1
Asanoma, K; Itakura, A; Izumi, H; Kato, K; Kohno, K; Kusunoki, S; Matsumura, Y; Onoyama, I; Sonoda, K; Suzuki, I; Tabu, K; Taga, T; Takeda, S; Yagi, H; Yoshida, S	1
Akada, K; Aoshima, K; Fujiwara, K; Fukunaga, E; Koyama, N; Miura, T; Miura, Y	1
Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK	1
Hori, K; Ito, K; Kasamatsu, Y; Kondo, E; Nishio, S; Takehara, K; Ushijima, K	1
Ackroyd, SA; Huang, ES; Kurnit, KC; Lee, NK	1
Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L	1
Backes, F; Birrer, MJ; Devor, EJ; Filiaci, V; Fleming, GF; Gonzalez-Bosquet, J; Guntupalli, S; Hanjani, P; Leslie, KK; McDonald, M; Miecznikowski, J; Ramirez, N; Reyes, HD; Samuelson, MI; Stephan, JM; Tewari, KS; Thiel, KW; Zhang, Y	1
Ran, X; Zhang, K; Zhou, P	1
Abitbol, J; Amajoud, Z; Eisenberg, N; Fatnassi, A; Gotlieb, WH; Kessous, R; Kogan, L; Laskov, I; Lau, S; Octeau, D; Salvador, S; Yasmeen, A	1
Arians, N; Krug, D	1
Binder, PS; Cusworth, S; Divine, LM; Hagemann, AR; Kuroki, LM; Massad, LS; McCourt, CK; Mutch, DG; Powell, MA; Thaker, PH; Zhao, P	1
Cho, S; Coombs, DM; Janát-Amsbury, MM; Jarboe, EA; Peterson, CM; Reyes, M; Taurin, S; Werner, TL; Yang, CH	1
Asher, R; Beale, P; Friedlander, M; Kwok, JB; Lee, CK; Park, SB; Selle, F	1
Grénman, S; Kallioniemi, A; Kuittinen, T; Laurila, M; Luukkaala, T; Mäenpää, J; Rovio, P; Staff, S	1
Bosse, T; Carinelli, S; Chowdhury, MN; Creutzberg, CL; de Boer, SM; Duvillard, P; Fyles, A; Haie-Meder, C; Hollema, H; Katsaros, D; McLachlin, CM; Mileshkin, L; Nout, RA; Powell, ME; Putter, H; Pyman, J; Singh, N; Smit, VTHBM; Verhoeven-Adema, KW; Wilson, G; Wortman, BG	1
Chhonker, YS; Do, AV; Ebeid, K; Geary, SM; Leslie, KK; Meng, X; Morris, AS; Murry, DJ; Pham, EL; Salem, AK; Thiel, KW; Wongrakpanich, A	1
de Melo, AC; de Moraes Lino da Silva, F; Fontes Dias, MS; Ingles Garces, ÁH; Moreira, E; Paulino, E; Saramago, M; Thuler, LCS	1
Attianese, D; Cosio, S; Fabrini, MG; Ferrero, A; Gadducci, A; Guerrieri, ME; Laliscia, C; Rossi, A	1
Banner, R; Kahan, J	1
Kudlowitz, D; Muggia, F; Musa, F; Velastegui, A	1
Hong, JH; Khurelbaatar, T; Lee, JK; Lee, NW; Lee, S; Min, KJ; Ryu, KJ; Song, JY	1
Aghajanian, C; Bender, DP; Carlson, JW; Dao, F; Dizon, DS; Filiaci, V; Gao, J; Lankes, HA; Levine, DA; Moore, K; O'Malley, DM; Powell, MA; Secord, AA; Soslow, RA; Stuckey, A; Tewari, KS	1
Dobashi, Y; Fujimori, K; Higa, A; Hiyama, G; Hoshi, H; Imai, JI; Ito, E; Katahira, K; Morisawa, G; Ryufuku, M; Soeda, S; Takagi, M; Takahashi, N; Tamura, H; Watanabe, S; Watanabe, T; Yanagisawa, Y	1
Abrahante, JH; Argenta, P; Bazzaro, M; Chang, Z; Clark, C; Emmings, E; Hellweg, R; Iizuka, Y; Konecny, G; Mooneyham, A; Schütz, F; Shetty, M; Starr, T	1
Arakawa, A; Asai-Sato, M; Hongo, A; Inokuchi, Y; Kamiura, S; Kato, K; Komiyama, S; Matsumoto, T; Sugiyama, T; Tabata, T; Takano, H; Takeshima, N	1
Brown, L; Chen, AM; Ganju, RG; Hoover, A; Jewell, A; Tawfik, O; TenNapel, M	1
Deng, L; Ding, J; Li, M; Li, T	1
Beck, HM; Fuh, KC; Guo, L; Hagemann, AR; Ilivicky, AR; Lawrence, JA; Lomonosova, E; McCourt, C; Mills, KA; Mutch, DG; Powell, MA; Quinn, JM; Roach, ST; Starks, CM; Thaker, PH	1
Abdo Filho, E; Alves de Oliveira Ferreira, P; Cabral Severino da Costa, S; Costa Miranda, V; de Freitas, D; Del Pilar Estevez Diz, M; Gabrielli, F; Gondim Meira Velame Azevedo, R; Harada, G; Rodrigues da Cunha Colombo Bonadio, R	1
Campbell, GB; Courtney-Brooks, M; Donovan, HS; Hay, CM; Taylor, SE; Wang, L	1
Asano, T; Hashimoto, S; Hirohashi, Y; Ikeo, K; Kanaseki, T; Kawai, N; Kubo, T; Kuroda, T; Mariya, T; Mizuuchi, M; Murai, A; Nakatsugawa, M; Saito, T; Tabuchi, Y; Torigoe, T; Tsukahara, T; Uno, S	1
Ju, DD; Li, J; Lu, H; Song, WW; Wang, JH; Yang, GD; Yang, XM; Zhang, CC; Zhang, R; Zhang, ZG; Zhu, LY	1
Li, L; Liu, S; Shou, H; Wang, Q	1
Kataoka, H; Kitawaki, J; Kokabu, T; Matsushima, H; Mori, T; Tarumi, Y; Yoriki, K	1
Kim, S; Kim, SW; Kim, YT; Lee, J; Li, LY; Nam, EJ	1
Aoki, D; Arai, M; Matoda, M; Michimae, H; Mizuno, M; Nakai, H; Nakanishi, T; Nomura, H; Saito, M; Saito, T; Sasagawa, M; Sugiyama, T; Takahashi, F; Tokunaga, H; Ushijima, K; Watanabe, Y; Yaegashi, N	1
Campos, S; Crotzer, D; Goebel, EA; Horowitz, NS; Konstantinopoulos, PA; Lee, EK; Lee, L; Lindeman, N; Matulonis, U; Nucci, MR; Raut, CP; Veneris, JT	1
Aghajanian, CA; Anderson, PR; Brewster, WR; Burke, JJ; DiSilvestro, PA; Filiaci, V; Huang, H; Kim, JW; Mannel, RS; McMeekin, DS; Miller, DS; Randall, ME; Rutherford, T; Salani, R; Small, W; Spirtos, NM; Terada, K; von Gruenigen, V; Yashar, CM	1
Allen, PK; Broaddus, RR; Chapman, BV; Eifel, PJ; Jhingran, A; Klopp, AH; Lu, KH; Ning, MS; Pardeshi, V; Soliman, PT; Swanick, CW; Westin, SN	1
Jang, JW; Lee, LJ	1
Ishibashi, T; Ishikawa, M; Ishikawa, N; Kurioka, H; Kyo, S; Minamoto, T; Nakamura, K; Nakayama, K; Nakayama, S; Ono, R; Onuma, H; Otsuki, Y; Razia, S; Yamashita, H	1
Armstrong, DK; Birrer, MJ; Darcy, KM; Deloia, JA; Krivak, TC; Lesnock, JL; Thrall, MM; Tian, C; Zahn, C	1
Aguayo, DA; Alonso, C; Bravo, EJ; Bravo, ML; Bustamante, EI; Comer, J; Cuello, MA; Gonzalez, PA; Gonzalez-Nilo, FD; Herrera, NS; Kato, S; Mendoza, HL; Morales, FA; Owen, GI; Solar, PA; Velasquez, LA; Vilos, C	1
Ata, O; Celik, C; Dogan, NU; Yavas, C; Yavas, G; Yılmaz, SA	1
Baba, T; Hamanishi, J; Kang, HS; Kharma, B; Konishi, I; Mandai, M; Matsumura, N; Murphy, SK; Yamaguchi, K; Yamanoi, K; Yoshioka, Y	1
Aghajanian, CA; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q	1
Shao, Z; Wen, Q; Yang, Z	1
Khemapech, N; Lertkhachonsuk, R; Oranratanaphan, S; Termrungruanglert, W; Vasurattana, A	1
Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP	1
Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T	1
Hashimoto, Y; Itoh, A; Kameda, Y; Kamoshida, S; Kato, H; Nishino, S; Ogane, N; Yasuda, M; Yokose, T	1
Abu-Rustum, NR; Alektiar, KM; Barakat, RR; Kollmeier, MA; Milgrom, SA; Sonoda, Y; Tew, WP	1
Chiappinelli, KB; Goodfellow, PJ; Kizer, NT; Ma, L; Thaker, PH; Trinkaus, KM; Yin, Y	1
Belau, A; Braicu, I; Ehmke, M; Koehler, G; Koensgen, D; Ledwon, P; Lichtenegger, W; Markmann, S; Mustea, A; Scharf, JP; Schneidewind, L; Sehouli, J; Sommer, H; Zygmunt, M	1
Gou, J; Li, Z; Min, W	1
Aquino-Parsons, C; Hoskins, P; Jutzi, L; Kwon, JS; Lim, P; Tinker, A	1
Fujiwara, K; Kigawa, J; Michimae, H; Nagao, S; Nishio, S; Okada, S; Otsuki, T; Suzuki, M; Tanabe, H; Tanioka, M	1
Hasegawa, K; Ishikawa, K; Kato, R; Kawai, S; Kawamura, K; Torii, Y; Tsukada, K; Udagawa, Y	1
Delaney, TF; Kahn, RS; Niemierko, A; Rochet, N; Russell, AH	1
Amadio, G; Masciullo, V; Scambia, G; Stefano, L	1
Boothe, D; Caputo, T; Chao, KS; Gupta, D; Holcomb, K; Nagar, H; Nori, D; Parashar, B; Parikh, A; Wernicke, AG; Yondorf, M	1
Che, YC; Li, X; Pan, XY; Zhang, Y	1
Chalapati, W; Suprasert, P	1
Borger, D; Bradford, LS; Clark, RM; Foster, R; Groeneweg, JW; Growdon, WB; Rauh-Hain, A; Rueda, BR; Zhang, L; Zukerberg, LR	1
Akslen, LA; Birkeland, E; Bredholt, T; Halle, MK; Krakstad, C; Salvesen, HB; Tangen, IL; Trovik, J; Werner, HM; Wik, E	1
Baranowski, W; Bodnar, L; Cichowicz, M; Cierniak, S; Dąbek, A; Gąsowska-Bodnar, A; Jerzak, M; Kozłowski, W	1
Al-Hammadi, N; Binder, PS; Fuh, K; Grigsby, P; Hagemann, A; Mutch, D; Pourabolghasem, S; Powell, M; Schwarz, J; Thaker, P; Wilkinson-Ryan, I	1
Al Moundhri, M; Bryant, A; Galaal, K; Lawrie, TA; Lopes, AD	1
Cho, CH; Cho, H; Kang, SB; Kim, BG; Kim, JH; Kim, SM; Nam, BH; Ryu, HS	1
Bydder, G; Bydder, M; Carmona, R; Gulaya, S; Mell, LK; Pritz, J; Vaida, F; Welch, CS; Williamson, CW; Zhu, H	1
Chen, JR; Yang, YC	1
Akman, T; Ellidokuz, H; Unal, OU; Yavuzsen, T; Yilmaz, AU	1
Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T	2
Abe, A; Kato, K; Kondo, E; Matoda, M; Nomura, H; Okamoto, S; Omatsu, K; Sueoka, K; Takeshima, N; Umayahara, K; Usami, T; Yamamoto, A	1
Drake, R; Escobar, PF; Nutter, B; Rasool, N; Rose, PG; Simpkins, F	1
Azodi, M; Damast, S; Higgins, SA; Mani, S; Ratner, E; Rutherford, T; Schwartz, PE; Silasi, DA; Young, MR; Yu, JB	1
Adachi, M; Aoki, D; Banno, K; Iida, M; Irie, H; Kobayashi, Y; Masuda, K; Nakamura, K; Nogami, Y; Tominaga, E; Umene, K; Yanokura, M	1
Chang-Halpenny, C; Hwang-Graziano, J; Lu, SM	1
Li, X; Liu, S	1
Bosch, WR; Erickson, BA; Gaffney, DK; Horowitz, NS; Jhingran, A; Mannel, RS; Matulonis, UA; Miller, BE; Moughan, J; Portelance, L; Small, W; Souhami, L; Viswanathan, AN; Winter, KA; Xiao, Y	1
Akiyama, M; Ito, F; Kitawaki, J; Matsushima, H; Mori, T; Sawada, M; Yamamoto, T	1
Barter, J; Dizon, D; Lisyanskaya, A; Manzyuk, L; McMeekin, S; Mukhopadhyay, P; Oaknin, A; Ringuette, S; Rosenberg, J; Scambia, G; Vergote, I	1
Fracasso, PM; Hoffman, JS; McMeekin, DS; Moore, KN; Rizack, T; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL	1
Afif, M; Benhmidou, N; Benjaafar, N; El kabous, M; Elkacemi, H; Kebdani, T; Kouhen, F; Majjaoui, S; Raiss, F	1
Fujiwara, K; Hasegawa, T; Hasumi, Y; Kigawa, J; Matsumoto, T; Nagao, S; Nakamura, K; Nishio, S; Okada, S; Otsuki, T; Shimada, M; Suzuki, M; Takano, M; Takei, Y; Takekuma, M; Tanabe, H	1
Aloisi, A; Angioli, R; Capriglione, S; De Cicco Nardone, C; Laraud, F; Miranda, A; Montera, R; Plotti, F; Scaletta, G; Terranova, C	1
Fleming, GF	1
Chu, C; Lin, LL; Rubin, S; Xu, MJ	1
Liu, C; Ran, X; Xiao, L; Yang, J; Zhang, K; Zhou, P	1
Elbassuiony, MA; Elsayed, AM; Helal, AM; Ismail, YM; Moneer, MM; Nassar, HR; Zeeneldin, AA	1
Furukawa, N; Ito, F; Nakai, T	1
Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H	1
Ali, MS; El-Husseiny, K; Motawei, H	1
Beriwal, S; Boisen, MM; Edwards, RP; Kelley, JL; Lesnock, JL; Richard, SD; Zorn, KK	1
Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N	1
Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C	1
Cirik, DA; Karalok, A; Koc, S; Tasci, T; Tulunay, G; Turan, T; Ureyen, I	1
Lang, B; Meng, L; Shang, C	1
Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW	1
Barillot, I; Charra Brunaud, C; Haie-Méder, C; Kerr, C; Peignaux, K; Thomas, L	1
Bondanelli, M; Degli Uberti, EC; Gentilin, E; Minoia, M; Tagliati, F; Zatelli, MC	1
Ahn, KJ; An, IS; An, S; Bae, S; Choi, YM; Kim, TJ; Lee, J; Lee, JH	1
Amant, F; Annibali, D; Cuppens, T; Depreeuw, J; Koskas, M; Lambrechts, D; Moens, S; Moerman, P	1
Aoki, D; Ishiwata, I; Iwamori, M; Kiguchi, K; Kubushiro, K; Mikami, M; Tanaka, K	1
Alkaisi, MM; Evans, JJ; Sykes, PH; Tan, LH	1
Ali, S; Moslemi-Kebria, M; Rose, PG; Simpkins, F	1
Chong, QY; Ding, K; Kong, X; Li, R; Li, X; Lobie, PE; Ma, L; Pandey, V; Qian, P; Wu, Z; Xiong, Z; Yang, Y; Yuan, Y; Zhu, T	1
An, M; Deng, J; Hu, M; Li, F; Li, H; Li, W; Lu, J; Ma, R; Wu, S; Zhang, L; Zhou, Y	1
Ben-Arye, E; Khamaisie, H; Lavie, O; Mahajna, J; Raz, OG; Samuels, N; Schiff, E	1
Aravantinos, G; Bafaloukos, D; Bamias, A; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Papadimitriou, CA; Pectasides, D	1
Jiang, SJ; Wang, XG; Wang, Y; Yang, YN	1
Hirabayashi, K; Hirasawa, T; Kajiwara, H; Kumaki, N; Mikami, M; Miyazawa, M; Muramatsu, T; Nakamura, N; Osamura, RY; Yasuda, M	1
Hoskins, PJ; Le, N; Mazgani, M	1
Bookman, MA; Hartenbach, EM; Koh, WJ; McMeekin, DS; Walker, JL	1
Akimoto, H; Ino, K; Ishida, Y; Isobe, K; Kajiyama, H; Kikkawa, F; Nawa, A; Shibata, K; Takikawa, O; Terauchi, M; Yamamoto, E; Yoshida, N	1
Kushimoto, T; Misawa, A; Nagao, M; Yasuda, M	1
Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Barakat, RR; Chi, DS; Makker, V; Soslow, RA	1
Foad, I; Hussein, T; Margergis, M; Mostafa, E; Sharawy, I	1
Atkinson, T; Horowitz, NS; Krag, KJ; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT	1
Jiang, SJ; Li, W; Mu, XY; Wang, Y; Zhang, S	1
Cella, D; DeGeest, K; Filiaci, V; Gibbons, SK; Homesley, HD; Lee, R; Long, HJ; Montag, A; Morris, RT; Spirtos, NM	1
Carey, MS; D'Souza, DP; Hammond, JA; Harle, IA; Kwon, JS; Lupe, K; Radwan, JS	1
Idris, T; Lang, U; Petru, E; Winter, R	1
Altaras, M; Ben-Harim, Z; Bruchim, I; Fishman, A; Shechter-Maor, G	1
A'Hern, R; Ang, JE; Blake, P; Coombes, I; Everard, M; Gabra, H; Gore, ME; Hall, G; Jenkins, A; Jones, RL; Kaye, SB; Keyzor, C; Shah, RN; Thomas, K	1
Amant, F; Berteloot, P; Capoen, A; Leunen, K; Moerman, P; Neven, P; Van Calster, B; Vandenput, I; Vergote, I	1
Alvarez, RD; Buchsbaum, DJ; Della Manna, DL; Frederick, PJ; Grizzle, WE; Kendrick, JE; Lin, HY; LoBuglio, AF; Oliver, PG; Stockard, CR; Straughn, JM; Zhou, T	1
Jakobsen, A; Steffensen, KD; Waldstrøm, M	1
Akamatsu, N; Aotani, E; Fujiwara, K; Kigawa, J; Miyagi, Y; Nagao, S; Noma, J; Numa, F; Okada, M	1
Eifel, PJ; Gershenson, DM; Jhingran, A; Klopp, AH; Lu, K; Ramondetta, L	1
Bae-Jump, VL; Boggess, JF; Gehrig, PA; Shafer, A; Zhou, C	1
Chang, TC; Chen, CH; Chen, RJ; Chien, CH; Chow, SN; Lee, WJ	1
Aoki, D; Kitagawa, R; Sagae, S; Sakuragi, N; Takeuchi, S; Watanabe, Y; Yaegashi, N	1
Amant, F; Berteloot, P; Leunen, K; Neven, P; Vandenput, I; Vergote, I	1
Narahara, H; Nasu, K; Nishida, M; Takai, N; Ueda, T	1
Busci, L; Carlini, L; Cipriani, S; De Marzi, P; Frigerio, L; Mangili, G; Parazzini, F; Viganò, R	1
Dangsuwan, P; Manchana, T	1
Aletti, GD; Cliby, WA; Gallenberg, M; Hartmann, L; Long, HJ; Nordquist, D	1
Godoy, H; Kesterson, JP; Lele, S	1
Hiramatsu, Y; Hongo, A; Kodama, J; Kusumoto, T; Nakamura, K; Seki, N	1
Chen, N; Jiang, T; Kong, B; Wang, XJ; Zhang, DD; Zhao, F; Zheng, W	1
Egawa-Takata, T; Enomoto, T; Fujita, M; Kimura, T; Matsuzaki, S; Miyake, T; Miyatake, T; Ueda, Y; Yokoyama, T; Yoshino, K	1
Chung, HH; Kang, SB; Kim, HS; Kim, JW; Lee, HP; Park, NH; Song, YS; Wu, HG	1
Hashimoto, M; Inoue, M; Kiyono, T; Kyo, S; Maida, Y; Mizumoto, Y; Mori, N; Nakamura, M; Ohno, S; Takakura, M	1
Kawana, K; Nakagawa, K; Nakagawa, S; Oda, K; Okuma, K; Yamashita, H	1
Aoki, D; Hatae, M; Hiura, M; Jobo, T; Katsumata, N; Konishi, I; Nomura, H; Takahashi, F; Watanabe, Y; Yaegashi, N	1
Cella, D; De Geest, K; Homesley, HD; Huang, H; Lee, R; Montag, A; Salani, R; Spirtos, NM	1
Beck, BB; Dai, D; Elmaoued, R; Fischer, E; Leslie, KK; Luo, W; Meng, X; Wu, F	1
Correa, R; Hoskins, PJ; Le, N	1
Fujishiro, N; Fujiwara, S; Maruoka, R; Ohmichi, M; Sekijima, T; Tanabe, A; Terai, Y; Yamashita, Y; Yu, S; Yuguchi, H	1
Coleman, RL; Fujita, H; Itani, Y; Ito, K; Kuroboshi, H; Nobunaga, T; Tsubamoto, H	1
Chen, YH; Li, XP; Wang, JL; Wang, Y; Wei, LH	1
Blomfield, P; Chan, W; McIntosh, R; Singh, P	1
Cibull, M; Cohn, DE; Gallion, HH; Gan, CM; Huh, WK; Richard, S	1
Lucci, JA; Pearson, MJ; Saigal, K; Schuman, S; Simpkins, F; Twiggs, LB; Walker, GR; Wolfson, AH; Wrenn, DC	1
Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP	1
Asada, M; Egawa-Takata, T; Enomoto, T; Fujita, M; Ito, K; Kimura, T; Kuragaki, C; Miyake, T; Miyatake, T; Morishige, K; Nagamatsu, M; Nakashima, R; Nishio, Y; Nishizaki, T; Ogita, K; Okazawa, M; Tsutsui, T; Ueda, Y; Wakimoto, A; Yamamoto, T; Yamasaki, M; Yoshino, K	1
Huang, Y; Li, T; Li, X; Liang, C; Ling, Y; Yang, Y	1
Ceccacci, I; Maneschi, F; Manicone, A; Pane, C; Perugini, A; Simeone, A	1
Li, T; Li, X; Shen, H; Wang, X; Xiao, L; Xu, C; Yang, Y; Zhang, X	1
Amant, F; Capoen, A; Coenegrachts, L; Moerman, P; Vandenput, I; Verbist, G; Vergote, I	1
Dogan, A; Ertas, IE; Gultekin, E; Gultekin, OE; Yildirim, Y	1
Hiramatsu, Y; Hongo, A; Imafuku, N; Joja, I; Kodama, J; Nakamura, K; Nishida, T; Niwa, I	1
Egawa-Takata, T; Enomoto, T; Fujita, M; Fujiwara, K; Kamiura, S; Kimura, T; Miyatake, T; Ohta, Y; Ueda, Y; Yoshino, K	1
Orlova, RV; Protasova, AE	1
Lee, SJ; Park, DC; Won, YS; Yeo, SG	1
Bae-Jump, VL; Gehrig, PA; Hanna, RK; Malloy, KM; Sun, L; Zhong, Y; Zhou, C	1
Li, T; Li, X; Shen, H; Wang, X; Xiao, L; Xu, C; Yang, Y	1
Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P	1
Amant, F; Neven, P; Vandenput, I; Vergote, I	1
Li, X; Shen, H; Wang, X; Xu, C; Yang, Y	1
Dong, L; Duan, T; Feng, Y; Zhang, Z; Zhou, Q; Zhu, Y	1
Aoki, H; Ikeda, S; Kitahara, Y; Luvsandagva, B; Minegishi, T; Murata, T; Nakamura, K	1
Agnoletti, V; Amadori, A; Ansaloni, L; Catena, F; Cavaliere, D; Coccolini, F; De Iaco, P; Di Battista, M; Framarini, M; Gazzotti, F; Ghermandi, C; Kopf, B; Pinna, AD; Saponara, M; Tauceri, F; Vallicelli, C; Verdecchia, GM	1
Fujiwara, H; Furuya, K; Imai, M; Jobo, T; Kudo, K; Nagata, C; Ochiai, K; Suzuki, M; Tanabe, H; Tanaka, T; Yamada, K; Yasuda, M	1
Abu-Rustum, NR; Aghajanian, C; Alektiar, KM; Barakat, RR; Damast, S; Gardner, GJ; Kiess, AP; Kollmeier, MA; Makker, V	1
Markman, M	1
Tanaka, J; Tanaka, T; Toujima, S	1
Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R	1
Byron, SA; Loch, DC; Pollock, PM	1
Li, M; Mao, N; Pan, L; Yin, J	1
Albitar, L; Brachova, P; Dai, D; Ianzini, F; Kosmacek, EA; Laidler, LL; Leslie, KK; Liu, D; Mackey, MA; Meng, X; Wang, X; Xiong, Z; Yang, S; Zhang, Y; Zhu, D	1
Godoy, HE; Lele, SB; Odunsi, K; Olawaiye, AB; Rauh-Hain, JA; Shahzad, MM	1
Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F	1
Bodurka, DC; Brown, J; Burke, TW; Eifel, PJ; Garcia, ME; Jhingran, A; Levy, LB; Lu, KH; Ramondetta, LM; Slomovitz, BM	1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA	1
Kanakura, Y; Kometani, K; Nakazawa, K; Niwa, K; Sekiya, T	1
Katsumata, N; Kitagawa, R; Yamanaka, Y	1
Bonnar, J; Gleeson, NC; McGuinness, EP; O'Toole, SA; Sheppard, BL; Yoneda, M	1
Kamura, T; Kawagoe, H; Kumagai, S; Matsuo, G; Nishida, T; Nishio, S; Ota, S; Sugiyama, T; Ushijima, K	1
Aoki, Y; Fujita, K; Kurata, H; Matsushita, H; Obata, H; Tanaka, K; Watanabe, M; Yahata, T	1
Hiramatsu, Y; Hongo, A; Kodama, J; Kudo, T; Mizutani, Y; Nagao, S; Okimoto, N; Yoshinouchi, M	1
Blessing, JA; Lee, RB; Lincoln, S; Rocereto, TF	1
Fushiki, H; Maeda, E; Yoshimoto, H	1
Kennedy, A; Longshore, SJ; Nurko, S; Taylor, JS	1
Ito, K; Koizumi, T; Niikura, H; Okamura, K; Yaegashi, N	1
Chang, SJ; Chen, HS; Chen, TC; Hsu, CY; Wang, TY; Yang, YC	1
Fowler, J; Markman, M	1
Chen, D; Hackl, W; Ortmann, O; Treeck, O	1
Burke, T; Cooper, J; Fontenesci, J; Greven, K; Underhill, K; Winter, K	2
Chida, M; Honma, H; Ishioka, S; Kudo, R; Mizumoto, H; Sagae, S; Saito, T; Tanaka, R; Terasawa, K	1
Brunetto, VL; Burger, RA; Burks, RT; Cella, D; Fleming, GF; Goodman, A; Kline, R; Look, KY; Munkarah, AR; Reid, GC	1
Kagami, T; Onoda, C; Tohya, T; Yoshimura, T	1
Bellone, S; Cannon, MJ; O'Brien, TJ; Pecorelli, S; Roman, JJ; Santin, AD	1
Bentley, RC; Filiaci, VL; Fleming, GF; Gallion, H; Herzog, T; Sorosky, J; Vaccarello, L	1
Hasumi, K; Hatae, M; Hirai, Y; Kuramoto, H; Kuzuya, K; Noda, K; Nozawa, S; Ochiai, K; Onose, R	1
Ino, K; Kajiyama, H; Kikkawa, F; Kondo, C; Mizokami, Y; Mizutani, S; Nomura, S; Shibata, K	1
Hoshiai, H; Watanabe, Y	1
Enomoto, T; Fujita, M; Murata, Y; Nakashima, R	1
Kakinoki, S; Takizawa, K	1
Atkinson, T; Berkowitz, R; Campos, S; Duska, LR; Goodman, A; Klein, A; Matulonis, U; McIntyre, JF; Muto, M; Seiden, MV	1
Alberts, DS; Hallum, AV; Hannigan, EV; Jiang, C; Liu, PY; Markman, M; Scudder, SA; Smith, GB; Smith, HO; Wilczynski, SP	1
Akram, T; Fanning, J; Maseelall, P	1
Kulp, B; Markman, M; Michener, CM; Peterson, G; Webster, KD	1
Nakahara, K; Ogino, T; Osanai, T; Tsuchiya, T	1
Ino, K; Kajiyama, H; Kikkawa, F; Kondo, C; Mizutani, S; Nawa, A; Nomura, S; Shibata, K; Terauchi, M	1
Berman, ML; Chan, JK; Hamilton, CA; Husain, A; Kapp, DS; Liou, WS; Osann, K; Teng, NN	1
Bissery, MC; Noguchi, K; Shakuto, S	1
Dai, D; Davies, S; Holmes, AM; Leslie, KK; Nguyen, T; Theele, DP; Verschraegen, C	1
Bamias, A; Bozas, GT; Dimopoulos, MA; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Vlahos, G	1
Hiramatsu, Y; Hongo, A; Kodama, J; Nakamura, K; Ojima, Y; Seki, N	1
Abu-Rustum, N; Aghajanian, C; Alektiar, KM; Barakat, R; Chi, DS; Dupont, J; Hensley, ML; Ishill, N; Sabbatini, P; Sovak, MA; Spriggs, DR	1
Carvalho, JP; Dias, ML; Graziani, SR; Maranhão, RC; Rodrigues, DG	1
Hidaka, T; Nakamura, T; Saito, S; Shima, T; Yuki, H	1
Hida, K; Ikeda, S; Ohta, H; Orito, S; Shimizu, S; Tatsuduki, A; Yoshikata, R	1
Darcy, KM; Fleming, GF; Mould, DR; Spriggs, D	1
Beatrice, S; De Marzi, P; Fazio, F; Frigerio, L; Gentile, C; Mangili, G; Rabaiotti, E; Viganò, R	1
Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T	1
Arimoto, T; Kawana, K; Nakagawa, S; Taketani, Y; Yano, T; Yasugi, T; Yoshikawa, H	1
Carey, MS; D'Souza, D; Gawlik, C; Kwon, J; Lupe, K; Nascu, P; Stitt, L; Whiston, F; Wong, E	1
Dowdy, SC; Hou, X; Jiang, S; Jiang, SW; Jin, F; Podratz, KC; Zhou, XC	1
Aoki, D; Banno, K; Hirao, N; Hirasawa, A; Kawaguchi, M; Susumu, N; Tsukazaki, K; Yanokura, M	1
Aydiner, A; Karagol, H; Kucucuk, S; Saip, P; Topuz, E; Uygun, K	1
Fukai, H; Matsumoto, H; Nakayama, Y; Ohta, Y; Sakamoto, H; Takami, M; Takimoto, T; Yamamoto, T	1
Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Rodriguez, GC; Secord, AA; Soper, JT	1
Filiaci, VL; Fleming, GF; Gallion, HH; McMeekin, DS; Rodgers, WH; Thigpen, JT	1
Filiaci, VL; Fleming, GF; Grushko, TA; Mundt, AJ; Olopade, OI; Ridderstråle, K	1
Wang, HJ; Zheng, WX	1
Gibb, RK; Grigsby, PW; Mutch, DG; Powell, MA; Rader, JS; Tierney, RM	1
Furukawa, N; Haruta, S; Kanayama, S; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Naruse, K; Oi, H; Sado, T; Sakata, M; Yamada, Y; Yoshida, S	1
Buttin, BM; Hardt, JL; Hoekstra, AV; Kim, JJ; Lurain, JR; Schink, JC; Singh, DK; Ward, EC	1
Economopoulos, T; Fountzilas, G; Gaglia, A; Gouveris, P; Kassanos, D; Koumarianou, A; Panayiotidis, J; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N	1
Elbendary, AA; Homesley, HD; Lowendowski, GS; Meltzer, NP; Nieves, L; Vaccarello, L	1
Koensgen, D; Mustea, A; Oskay-Ozcelik, G; Sehouli, J	1
Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA	1
Bauerschlag, DO; Hilpert, F; Jonat, W; Maass, N; Meinhold-Heerlein, I; Mundhenke, C; Roesel, F; Schem, C; Sturner, KH; Weigel, MT	1
Khansur, T; Thigpen, T; Vance, RB	1
Beller, U; Hiller, N; Hornreich, G; Lavie, O; McDaniel, C; Neuman, M; Winograd, B	1
Hayakawa, S; Sato, S; Takano, T; Wagazuma, S; Yajima, A	1
Kavanagh, JJ; Kudelka, AP	1
Hoskins, PJ; Swenerton, KD; Woo, HL	1
Arbuck, SG	1
Ball, HG; Blessing, JA; Lentz, SS; Mutch, DG	1
Gabriele, A; Lissoni, A; Losa, G; Mangioni, C; Parma, G; Zanetta, G	1
Kristensen, G; Tropé, C	1
Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K	2
Edwards, RP; Hart, LA; Kelley, JL; Kunschner, AJ; Price, FV	1
Gabriele, A; Gorga, G; Landoni, F; Lissoni, A; Mangioni, C; Sessa, C; Tumolo, S	1
Rowinsky, EK	1
Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y	1
Spencer, CM; Wiseman, LR	1
Charnsangavej, C; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vasuratna, A; Verschraegen, CF; Wootipoom, V	1
Parrish, EA; Rinehart, CA; Watson, JM	1
Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H	1
Eltabbakh, GH; Garafano, LL; Hammond, JM; Moody, J	1
Hatae, M; Kouno, S; Maeda, Y; Nakamura, T; Onishi, Y; Yamamoto, F	1
Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ	1
Aravantinos, G; Dimopoulos, MA; Georgoulias, V; Gika, D; Karpathios, S; Moulopoulos, LA; Papadimitriou, CA; Stamatelopoulos, S	1
Carter, P; Harmer, C; Lofts, FJ; Pettengell, R; Szlosarek, PW; Young, M	1
Bristow, RE; Grumbine, FC; Montz, FJ; Rosenshein, NB; Zerbe, MJ	1
Hiramatsu, HP; Kikuchi, Y; Nagata, I; Seto, H	1
Fujiyoshi, K; Hirai, N; Kamura, T; Komai, K; Nishida, T; Ota, S; Sugiyama, T; Ushijima, K	1
Ball, HG; Copeland, LJ; Fleming, GF; Fowler, JM; Fracasso, PM; Greer, BE; Horowitz, I; McGuire, WP; Schilder, RJ; Sutton, G; Waggoner, SE	1
Aletti, G; Beatrice, S; Carnelli, M; Ferrari, A; Frigerio, L; Garavaglia, E; Mangili, G	1
Debus, G; Schuhmacher, I	1
Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H	1
Kanno, H; Kuzuta, T; Matsui, H; Seki, K; Sekiya, S; Yamazawa, K	1
Hirai, N; Kamura, T; Komai, K; Kumagai, S; Nishida, T; Ota, S; Sugiyama, T; Ushijima, K	1
Acquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F	1
Kim, RY	1

Reviews

23 review(s) available for paclitaxel and Cancer of Endometrium

Article	Year
Beyond Serous: Treatment Options for Rare Endometrial Cancers. Current treatment options in oncology, 2022, Volume: 23, Issue:11 Topics: Carboplatin; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Lymph Node Excision; Paclitaxel	2022
Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecologic oncology, 2022, Volume: 167, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies	2022
PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC cancer, 2023, Nov-29, Volume: 23, Issue:1 Topics: B7-H1 Antigen; Carboplatin; Endometrial Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Paclitaxel; Programmed Cell Death 1 Receptor; Randomized Controlled Trials as Topic	2023
Circular RNAs: Novel biomarkers for cervical, ovarian and endometrial cancer (Review). Oncology reports, 2020, Volume: 44, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Early Detection of Cancer; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; RNA, Circular; Survival Rate; Uterine Cervical Neoplasms	2020
Scalp metastasis from endometrial carcinoma: a case report and literature review. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2018, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Consolidation Chemotherapy; Diabetes Mellitus, Type 2; Endometrial Neoplasms; Female; Head and Neck Neoplasms; Humans; Hysterectomy; Liver Neoplasms; Middle Aged; Obesity; Paclitaxel; Salpingo-oophorectomy; Scalp; Skin Neoplasms	2018
An update on the pharmacotherapy for endometrial cancer. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:18 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Practice Guidelines as Topic; Radiography; Randomized Controlled Trials as Topic	2013
Adjuvant chemotherapy for advanced endometrial cancer. The Cochrane database of systematic reviews, 2014, May-15, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic	2014
[Brain metastasis of endometrial cancer: report of a case and review of literature]. The Pan African medical journal, 2015, Volume: 20 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel	2015
Second-Line Therapy for Endometrial Cancer: The Need for Better Options. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31 Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Fluorouracil; Gabapentin; gamma-Aminobutyric Acid; Humans; Medical Oncology; Middle Aged; Paclitaxel; Receptors, Progesterone; Rectal Neoplasms; Stroke; TOR Serine-Threonine Kinases; Treatment Outcome	2015
[Latest information of therapeutic approach for endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate	2002
Current treatment options for endometrial cancer. Expert review of anticancer therapy, 2004, Volume: 4, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Receptor, ErbB-2; Risk Factors; Survival Analysis; Trastuzumab	2004
[Recent outline of chemotherapy for uterine endometrial cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Paclitaxel	2004
[Activity of paclitaxel, epirubicin and carboplatin in patients with advanced or recurrent endometrial cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Epirubicin; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome	2004
[Efficacy of cancer chemotherapy on patients with recurrent endometrial carcinoma]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk	2004
[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2007, Volume: 36, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma in Situ; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Paclitaxel; Precancerous Conditions; Radiotherapy, Adjuvant; Uterine Neoplasms	2007
New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Critical reviews in oncology/hematology, 2008, Volume: 67, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Doxorubicin; Endometrial Neoplasms; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Staging; Paclitaxel; Treatment Outcome	2008
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Uterine Cervical Neoplasms	1995
[Chemotherapy of uterine endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoplasm Invasiveness; Paclitaxel	1995
Systemic therapy for gynecologic cancer. Current opinion in oncology, 1993, Volume: 5, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Uterine Cervical Neoplasms; Uterine Neoplasms	1993
Current status of chemotherapy in gynecologic cancer. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms	1997
Paclitaxel pharmacology and other tumor types. Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19 Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Endometrial Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphoma; Male; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Platinum Compounds; Sarcoma, Kaposi; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine	1997
Paclitaxel. An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs & aging, 1998, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Uterine Cervical Neoplasms	1998
Recent advances in the treatment of gynecologic malignancies: an overview of the GOG phase III trials. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Endometrial Neoplasms; Female; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Treatment Outcome; Uterine Cervical Neoplasms; Vulvar Neoplasms	2002

Trials

81 trial(s) available for paclitaxel and Cancer of Endometrium

Article	Year
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study. Gynecologic oncology, 2022, Volume: 164, Issue:2 Topics: Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Functional Status; Gastrointestinal Diseases; Humans; Neoplasm Staging; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Quality of Life	2022
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer science, 2022, Volume: 113, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Neoplasm Staging; Paclitaxel	2022
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer research communications, 2022, Volume: 2, Issue:10 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Paclitaxel	2022
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. The New England journal of medicine, 2023, Jun-08, Volume: 388, Issue:23 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Mismatch Repair; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Paclitaxel	2023
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. The New England journal of medicine, 2023, 06-08, Volume: 388, Issue:23 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Mismatch Repair; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Microsatellite Instability; Neoplasm Recurrence, Local; Paclitaxel	2023
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecologic oncology, 2023, Volume: 172 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Female; Humans; Intercellular Signaling Peptides and Proteins; Ovarian Neoplasms; Paclitaxel	2023
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet. Oncology, 2023, Volume: 24, Issue:3 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Paclitaxel	2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature, 2023, Volume: 620, Issue:7973 Topics: Animals; Biopsy; Carboplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; Humans; Mice; Netrin-1; Paclitaxel; RNA-Seq; Single-Cell Gene Expression Analysis; Tumor Microenvironment	2023
Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial. Gynecologic oncology, 2019, Volume: 155, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Postoperative Care; Recurrence; Risk Factors; Young Adult	2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. Gynecologic oncology, 2019, Volume: 155, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Progression-Free Survival; Prospective Studies	2019
[Clinical implications of the PORTEC-3 trial for the treatment of high-risk endometrial cancer]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:4 Topics: Area Under Curve; Brachytherapy; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Risk Factors; Survival Rate	2020
Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 08-01, Volume: 26, Issue:15 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Administration Schedule; Endometrial Neoplasms; Endometrium; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Receptor, ErbB-2; Survival Analysis; Trastuzumab	2020
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic oncology, 2021, Volume: 161, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Caveolin 1; Dasatinib; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Pilot Projects; Receptor, EphA2; Signal Transduction; Survival Rate	2021
A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial. Journal of gynecologic oncology, 2021, Volume: 32, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2021
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer. Gynecologic oncology, 2021, Volume: 162, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines	2021
[Radiochemotherapy improves failure-free survival in stage III endometrial cancer : Final results of the PORTEC-3 trial]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2017, Volume: 193, Issue:12 Topics: Brachytherapy; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prospective Studies	2017
Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Neurotoxicity Syndromes; Outcome Assessment, Health Care; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Physicians; Polymorphism, Single Nucleotide; Prognosis; Risk Factors; Severity of Illness Index; Surveys and Questionnaires; Survival Rate; Young Adult	2017
Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 02-01, Volume: 29, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Patient Selection; Radiotherapy	2018
A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic oncology, 2018, Volume: 150, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Endometrial Neoplasms; Epothilones; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Sirolimus	2018
Adjuvant Carboplatin and Paclitaxel Chemotherapy Followed by Radiotherapy in High-Risk Endometrial Cancer: A Retrospective Analysis. Journal of global oncology, 2018, Volume: 4 Topics: Aged; Antineoplastic Agents, Phytogenic; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate	2018
Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. JAMA oncology, 2019, Jun-01, Volume: 5, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Risk; Taxoids; Treatment Outcome	2019
Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 07-20, Volume: 37, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pelvis; Prospective Studies; Radiotherapy, Adjuvant; Vagina; Young Adult	2019
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. British journal of cancer, 2013, Apr-02, Volume: 108, Issue:6 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate	2013
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate	2013
Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology). Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Feasibility Studies; Female; Follow-Up Studies; Germany; Hematologic Diseases; Humans; Incidence; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Survival Analysis	2013
A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study. International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Chemoradiotherapy; Confidence Intervals; Disease-Free Survival; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Care; Prospective Studies; Radiation-Sensitizing Agents; Republic of Korea; Survival Analysis	2014
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:11 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Risk Assessment; Risk Factors; Thrombocytopenia; Treatment Outcome	2014
A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). Gynecologic oncology, 2015, Volume: 136, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2015
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer, 2015, Jul-01, Volume: 121, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Paclitaxel; Postoperative Period; Radiotherapy, Intensity-Modulated	2015
Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecologic oncology, 2015, Volume: 138, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Endometrial Neoplasms; Epothilones; Female; Humans; Middle Aged; Paclitaxel; Survival Rate	2015
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology, 2015, Volume: 138, Issue:1 Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Paclitaxel	2015
Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate	2016
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids	2016
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Oncology, 2016, Volume: 17, Issue:8 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate	2016
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecologic oncology, 2008, Volume: 111, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Topotecan	2008
Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study. Gynecologic oncology, 2009, Volume: 112, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel	2009
Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma. Journal of the Egyptian National Cancer Institute, 2007, Volume: 19, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Prognosis; Radiotherapy Dosage; Survival Rate; Treatment Outcome	2007
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecologic oncology, 2009, Volume: 112, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life	2009
A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecologic oncology, 2009, Volume: 112, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy	2009
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel	2009
Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:5 Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Treatment Outcome	2009
Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Survival Analysis	2009
Adjuvant treatment with concomitant radiotherapy and chemotherapy in high-risk endometrial cancer: a clinical experience. Gynecologic oncology, 2010, Volume: 116, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiotherapy, Adjuvant; Risk Factors; Survival Rate	2010
Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecologic oncology, 2010, Volume: 116, Issue:3 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Erythrocyte Transfusion; Female; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Hemoglobins; Humans; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel; Taxoids; Young Adult	2010
From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome	2010
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome	2011
Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184. Gynecologic oncology, 2010, Volume: 119, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Self Report	2010
A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial). Gynecologic oncology, 2011, Volume: 120, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Quality of Life; Risk Factors	2011
A Phase I Study using low-dose fractionated whole abdominal radiotherapy as a chemopotentiator to full-dose cisplatin for optimally debulked stage III/IV carcinoma of the endometrium. Gynecologic oncology, 2011, Volume: 122, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel	2011
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome	2010
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Remission Induction; Retrospective Studies	2011
Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies	2012
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:5 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate	2012
A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecologic oncology, 2013, Volume: 129, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brachytherapy; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Administration Schedule; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Prospective Studies; Salpingectomy; Survival Analysis; Treatment Outcome	2013
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Vorinostat	2013
Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, 2003, Volume: 88, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2003
Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. International journal of radiation oncology, biology, physics, 2004, May-01, Volume: 59, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Radiotherapy Dosage; Radiotherapy, Adjuvant; Recurrence; Survival Analysis	2004
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nervous System Diseases; Paclitaxel; Proportional Hazards Models; Recombinant Proteins; Survival Analysis	2004
Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Recombinant Proteins; Treatment Outcome	2004
Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. Gynecologic oncology, 2004, Volume: 94, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2004
A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecologic oncology, 2005, Volume: 96, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Recombinant Proteins; Risk Factors	2005
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecologic oncology, 2005, Volume: 96, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2005
Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. European journal of obstetrics, gynecology, and reproductive biology, 2007, Volume: 131, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Treatment Outcome; Uterus	2007
Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecologic oncology, 2006, Volume: 103, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Risk Factors; Treatment Outcome	2006
Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Chemistry, Pharmaceutical; Cholesterol; Emulsions; Endometrial Neoplasms; Excipients; Female; Genital Neoplasms, Female; Half-Life; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Triglycerides; Uterine Cervical Neoplasms	2007
Population analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group study. British journal of clinical pharmacology, 2006, Volume: 62, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Doxorubicin; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Prospective Studies; Survival Analysis	2006
Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC cancer, 2006, Jul-25, Volume: 6 Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Ploidies; Radiation Dosage; Radiation-Sensitizing Agents; Recurrence; Risk Factors; Treatment Failure	2006
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2006, Volume: 18, Issue:1-3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors	2006
The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecologic oncology, 2007, Volume: 106, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome	2007
A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. International journal of clinical oncology, 2008, Volume: 13, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Paclitaxel; Uterine Cervical Neoplasms	2008
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. Gynecologic oncology, 2008, Volume: 110, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence	2008
A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecologic oncology, 1996, Volume: 62, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Recurrence; Treatment Outcome	1996
Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Evaluation Studies as Topic; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Treatment Outcome	1996
A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Cause of Death; Chemotherapy, Adjuvant; Disease Progression; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Radiography; Remission Induction; Risk Factors; Salvage Therapy; Sensation Disorders; Survival Rate; Thrombocytopenia	1997
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Uterine Cervical Neoplasms	1997
[Evaluation of paclitaxel and carboplatin in patients with endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Leukopenia; Middle Aged; Neutropenia; Paclitaxel	2000
Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecologic oncology, 2000, Volume: 78, Issue:1 Topics: Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Taxoids	2000
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-15, Volume: 19, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Male; Middle Aged; Paclitaxel; Peripheral Nerves	2001
Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecologic oncology, 2001, Volume: 81, Issue:1 Topics: Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Endometrial Neoplasms; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy; Radiotherapy, Adjuvant; Risk Factors	2001
Weekly 1 hour paclitaxel infusion in patients with recurrent gynecological tumors: a pilot study. Japanese journal of clinical oncology, 2001, Volume: 31, Issue:8 Topics: Ambulatory Care; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Salvage Therapy; Uterine Cervical Neoplasms	2001
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis	2001

Other Studies

233 other study(ies) available for paclitaxel and Cancer of Endometrium

Article	Year
CMBs carrying PTX and CRISPR/Cas9 targeting Molecular medicine reports, 2021, Volume: 24, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; CRISPR-Cas Systems; Cyclin-Dependent Kinase Inhibitor p21; Disease Progression; Drug Therapy; Endometrial Neoplasms; Female; Gene Editing; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Microbubbles; Paclitaxel; Plasmids; Proliferating Cell Nuclear Antigen; Receptor, ErbB-2	2021
Effect of CMB Carrying PTX and CRISPR/Cas9 on Endometrial Cancer Naked Mouse Model. Journal of healthcare engineering, 2022, Volume: 2022 Topics: Animals; CRISPR-Cas Systems; Disease Models, Animal; Endometrial Neoplasms; Female; Glycogen Synthase Kinase 3; Humans; Mammals; Mice; Paclitaxel	2022
Maintenance therapy for long-term control of high-grade endometrial stromal sarcoma. BMJ case reports, 2022, May-12, Volume: 15, Issue:5 Topics: Carboplatin; COVID-19 Drug Treatment; Endometrial Neoplasms; Female; Humans; Paclitaxel; Pandemics; Sarcoma, Endometrial Stromal	2022
The Glutaminase Inhibitor Compound 968 Exhibits Potent Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:2 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Glutaminase; Glutamine; Humans; Mice; Paclitaxel; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases	2023
GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis. Molecular cancer therapeutics, 2022, 08-02, Volume: 21, Issue:8 Topics: Antineoplastic Agents; Endometrial Neoplasms; Female; Glycolysis; Humans; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases	2022
Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis. Gynecologic oncology, 2022, Volume: 166, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies	2022
Exceptional widespread, life threatening lung metastasis in stage IA ovarian endometrioid carcinoma: A case report. Taiwanese journal of obstetrics & gynecology, 2022, Volume: 61, Issue:5 Topics: Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2022
The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival. Cellular and molecular life sciences : CMLS, 2022, Sep-19, Volume: 79, Issue:10 Topics: Animals; Carboplatin; Cell Proliferation; Cytokines; Endometrial Neoplasms; Epidermal Growth Factor; Female; Humans; MAP Kinase Kinase 5; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappa B; Paclitaxel	2022
Circ_0039569 contributes to the paclitaxel resistance of endometrial cancer via targeting miR-1271-5p/PHF6 pathway. Anti-cancer drugs, 2022, 10-01, Volume: 33, Issue:9 Topics: Cell Proliferation; Endometrial Neoplasms; Female; Humans; MicroRNAs; Paclitaxel; Repressor Proteins; RNA, Circular; Transcription Factors	2022
Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer. BioMed research international, 2022, Volume: 2022 Topics: Biomarkers, Tumor; Carcinoma, Endometrioid; Cisplatin; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Prognosis; RNA, Long Noncoding; Tumor Suppressor Protein p53	2022
Tislelizumab Combined with Carboplatin-Paclitaxel for Treatment of Metastatic or Recurrent Endometrial Cancer: a Retrospective Clinical Study. Clinical laboratory, 2022, Nov-01, Volume: 68, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies	2022
STAT3 inhibitor BBI608 reduces patient-specific primary cell viability of cervical and endometrial cancer at a clinical-relevant concentration. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:3 Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Endometrial Neoplasms; Female; Humans; Paclitaxel; STAT3 Transcription Factor; Uterine Cervical Neoplasms	2023
JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer. International journal of clinical oncology, 2023, Volume: 28, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel	2023
A ciprofloxacin derivative with four mechanisms of action overcomes paclitaxel resistance in p53-mutant and MDR1 gene-expressing type II human endometrial cancer. Biomaterials, 2023, Volume: 296 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Paclitaxel; Tumor Suppressor Protein p53	2023
[An exceptional venous pattern in a patient with cancer]. Nederlands tijdschrift voor geneeskunde, 2023, 04-19, Volume: 167 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Endometrial Neoplasms; Female; Humans; Paclitaxel	2023
The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells. Medicina (Kaunas, Lithuania), 2023, May-21, Volume: 59, Issue:5 Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptor Tyrosine Kinase-like Orphan Receptors	2023
LncRNA RBAT1 reduces chemosensitivity of cancer cells to carboplatin/paclitaxel by sponging miR‑27b in endometrial carcinoma. Journal of ovarian research, 2023, Jul-27, Volume: 16, Issue:1 Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carboplatin; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Paclitaxel; RNA, Long Noncoding	2023
Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer International journal of oncology, 2023, Volume: 63, Issue:3 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Mice; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-akt	2023
Bulletin du cancer, 2023, Volume: 110, Issue:6S Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Endometrial Neoplasms; Female; Hormones; Humans; Paclitaxel	2023
Knockdown of PROM2 Enhances Paclitaxel Sensitivity in Endometrial Cancer Cells by Regulating the AKT/FOXO1 Pathway. Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:19 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Female; Forkhead Box Protein O1; Humans; Membrane Glycoproteins; Paclitaxel; Proto-Oncogene Proteins c-akt	2023
ALDH-Dependent Glycolytic Activation Mediates Stemness and Paclitaxel Resistance in Patient-Derived Spheroid Models of Uterine Endometrial Cancer. Stem cell reports, 2019, 10-08, Volume: 13, Issue:4 Topics: Aldehyde Dehydrogenase; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Activation; Female; Gene Expression; Glycolysis; Humans; Neoplastic Stem Cells; Paclitaxel; Spheroids, Cellular; Tumor Cells, Cultured	2019
LncRNA HEIH Enhances Paclitaxel-Tolerance of Endometrial Cancer Cells via Activation of MAPK Signaling Pathway. Pathology oncology research : POR, 2020, Volume: 26, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Paclitaxel; RNA, Long Noncoding	2020
[Preoperative systemic treatment of locally and locoregionally advanced high-risk endometrial cancer]. Orvosi hetilap, 2020, Volume: 161, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Endometrial Neoplasms; Female; Humans; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Ovariectomy; Paclitaxel; Survival Rate; Treatment Outcome	2020
Well-Differentiated Papillary Mesothelioma With Two Synchronous Serous Gynaecologic Carcinomas in a 62-Year-Old Woman: Lessons Learned for the Gynaecologic Surgeon. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2020, Volume: 42, Issue:10 Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Hysterectomy; Mesothelioma; Middle Aged; Paclitaxel; Pelvic Bones; Treatment Outcome	2020
Four versus six chemotherapy cycles in endometrial carcinoma with a high risk of recurrence: a retrospective study. Japanese journal of clinical oncology, 2020, Aug-04, Volume: 50, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Probability; Retrospective Studies; Risk Factors; Treatment Outcome	2020
[Overexpression of leukemia inhibitory factor enhances chemotherapy tolerance of endometrial cancer cells Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020, Jan-30, Volume: 40, Issue:1 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Leukemia Inhibitory Factor; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT3 Transcription Factor	2020
Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma. Asian Pacific journal of cancer prevention : APJCP, 2020, May-01, Volume: 21, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate	2020
ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. Asian Pacific journal of cancer prevention : APJCP, 2020, Jul-01, Volume: 21, Issue:7 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Follow-Up Studies; Glutathione S-Transferase pi; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; X-ray Repair Cross Complementing Protein 1	2020
MicroRNA Let-7c Contributes to Paclitaxel Resistance via Aurora-B in Endometrial Serous Carcinoma. The Tohoku journal of experimental medicine, 2020, Volume: 251, Issue:4 Topics: Apoptosis; Aurora Kinase B; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Molecular Targeted Therapy; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel	2020
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent. Scientific reports, 2020, 07-29, Volume: 10, Issue:1 Topics: Alkylating Agents; Animals; Antineoplastic Agents; Cattle; Cisplatin; Cross-Linking Reagents; DNA; Dogs; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Endometrial Neoplasms; Female; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Inhibitory Concentration 50; KB Cells; Ligands; Mice; Mice, Inbred C57BL; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Rats; Triple Negative Breast Neoplasms; Vinca Alkaloids; Xenograft Model Antitumor Assays	2020
Safe administration of chemotherapy in mast cell activation syndrome. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Mastocytosis; Middle Aged; Paclitaxel	2021
MicroRNA‑34b expression enhances chemosensitivity of endometrial cancer cells to paclitaxel. International journal of oncology, 2020, Volume: 57, Issue:5 Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; MicroRNAs; Paclitaxel; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc	2020
Development of a patient-derived explant model for prediction of drug responses in endometrial cancer. Gynecologic oncology, 2021, Volume: 160, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Chemotherapy, Adjuvant; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Endometrium; Feasibility Studies; Female; Genetic Heterogeneity; Humans; Hysterectomy; Immune Checkpoint Inhibitors; Paclitaxel; Pilot Projects; Precision Medicine; Tissue Culture Techniques; Tumor Microenvironment	2021
In Silico Inference of Synthetic Cytotoxic Interactions from Paclitaxel Responses. International journal of molecular sciences, 2021, Jan-22, Volume: 22, Issue:3 Topics: Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Endometrial Neoplasms; Female; Gene Regulatory Networks; Genes, Tumor Suppressor; Genome, Human; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Mutation; Paclitaxel; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Urogenital Neoplasms	2021
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecologic oncology, 2021, Volume: 161, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Epothilones; Female; Genes, p53; Humans; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Randomized Controlled Trials as Topic; Sirolimus; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53	2021
Sirtuin2 correlates with lymph node metastasis, increased FIGO stage, worse overall survival, and reduced chemosensitivity to cisplatin and paclitaxel in endometrial cancer. Irish journal of medical science, 2022, Volume: 191, Issue:1 Topics: Cisplatin; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies	2022
YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer. Scientific reports, 2021, 02-18, Volume: 11, Issue:1 Topics: Antigens, Neoplasm; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Paclitaxel; RNA-Binding Proteins	2021
Real-world database analysis of the characteristics and treatment patterns of patients with endometrial cancer in Japan. Current medical research and opinion, 2021, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Paclitaxel; Retrospective Studies	2021
Preliminary evaluation on the beneficial effects of pioglitazone in the treatment of endometrial cancer. Medical oncology (Northwood, London, England), 2021, May-18, Volume: 38, Issue:6 Topics: Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Endometrial Neoplasms; Estradiol; Ethylnitrosourea; Female; Mice; Paclitaxel; Pioglitazone; Survival Rate; Uterus	2021
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecologic oncology, 2021, Volume: 162, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Decision Trees; Drug Costs; Endometrial Neoplasms; Female; Humans; Markov Chains; Microsatellite Instability; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Phenylurea Compounds; Progression-Free Survival; Quality of Life; Quality-Adjusted Life Years; Quinolines	2021
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecologic oncology, 2017, Volume: 146, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Prognosis; Retrospective Studies; Stathmin; Survival Rate	2017
Autophagy plays an important role in stemness mediation and the novel dual function of EIG121 in both autophagy and stemness regulation of endometrial carcinoma JEC cells. International journal of oncology, 2017, Volume: 51, Issue:2 Topics: Autophagy; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endometrium; Female; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Paclitaxel	2017
Dose dense carboplatin paclitaxel improves progression free survival in patients with endometrial cancer. Gynecologic oncology, 2017, Volume: 147, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Survival Analysis	2017
Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer. Gynecologic oncology, 2017, Volume: 147, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Retrospective Studies; Taxoids	2017
Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018, Volume: 28, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Growth Processes; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Indoles; Mice; Mice, Nude; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinolines; Random Allocation; Receptor, Fibroblast Growth Factor, Type 2; Xenograft Model Antitumor Assays	2018
Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells Anticancer research, 2017, Volume: 37, Issue:12 Topics: Antineoplastic Agents; Calcitriol; Carboplatin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Receptors, Calcitriol; Receptors, Estrogen; Receptors, Progesterone; Vitamins	2017
Synthetically lethal nanoparticles for treatment of endometrial cancer. Nature nanotechnology, 2018, Volume: 13, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Endometrial Neoplasms; Female; Humans; Indoles; Mice, Nude; Mutation; Nanomedicine; Nanoparticles; Paclitaxel; Tumor Suppressor Protein p53	2018
Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA). Medical oncology (Northwood, London, England), 2018, Jan-31, Volume: 35, Issue:3 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate	2018
Rates, Sites and Times of Recurrence and Clinical Outcome of Endometrial Cancer Patients with Histologically-positive Nodes: An Italian Two-center Retrospective Study. Anticancer research, 2018, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies	2018
A localised skin reaction after chemotherapy. BMJ (Clinical research ed.), 2018, 03-01, Volume: 360 Topics: Antineoplastic Agents, Phytogenic; Drug Eruptions; Endometrial Neoplasms; Erythema; Female; Humans; Middle Aged; Paclitaxel; Radiodermatitis; Spinal Neoplasms	2018
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Drug Administration Schedule; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Mullerian Ducts; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Paclitaxel; Retrospective Studies; Treatment Outcome	2018
Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. Oncology reports, 2018, Volume: 40, Issue:2 Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Gene Expression; Humans; Male; Mice; Organoids; Paclitaxel; Xenograft Model Antitumor Assays	2018
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. Hormones & cancer, 2018, Volume: 9, Issue:5 Topics: Biomarkers; Carboplatin; Endometrial Neoplasms; Female; Humans; Male; Paclitaxel; Sequence Analysis, RNA	2018
Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial). International journal of clinical oncology, 2019, Volume: 24, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Prospective Studies; Safety; Survival Rate; Young Adult	2019
Undifferentiated Endometrial Carcinomas: Clinicopathologic Characteristics and Treatment Outcomes. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2018, Volume: 28, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Lymph Nodes; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate	2018
Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells. BioMed research international, 2018, Volume: 2018 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Imidazoles; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases	2018
SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. Gynecologic oncology, 2018, Volume: 151, Issue:2 Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Neoplasm; Tubulin Modulators; Xenograft Model Antitumor Assays	2018
Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance? Gynecologic oncology, 2019, Volume: 152, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cohort Studies; Endometrial Neoplasms; Female; Frailty; Humans; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Prospective Studies	2019
Clonal analysis revealed functional heterogeneity in cancer stem-like cell phenotypes in uterine endometrioid adenocarcinoma. Experimental and molecular pathology, 2019, Volume: 106 Topics: Animals; Carboplatin; Carcinoma, Endometrioid; Clone Cells; Culture Media; DNA, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Neoplastic Stem Cells; Paclitaxel; Phenotype; Sequence Analysis, DNA; Serum; Spheroids, Cellular; Tumor Cells, Cultured	2019
Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma. EBioMedicine, 2019, Volume: 40 Topics: Animals; Biomarkers; Calcium-Binding Proteins; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Mice; Neoplasm Grading; Neoplasm Staging; Neoplastic Stem Cells; Paclitaxel; Wnt Signaling Pathway; Xenograft Model Antitumor Assays	2019
Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma. Gene, 2019, Apr-30, Volume: 694 Topics: 3' Untranslated Regions; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Jumonji Domain-Containing Histone Demethylases; MicroRNAs; Nuclear Proteins; Paclitaxel; Repressor Proteins; Signal Transduction; Theranostic Nanomedicine; Up-Regulation	2019
Antitumor effect of XCT790, an ERRα inverse agonist, on ERα-negative endometrial cancer cells. Cellular oncology (Dordrecht), 2019, Volume: 42, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endometrial Neoplasms; ERRalpha Estrogen-Related Receptor; Estrogen Receptor alpha; Female; Humans; Mice; Mice, Inbred BALB C; Nitriles; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Transcription, Genetic; Tubulin; Xenograft Model Antitumor Assays	2019
Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2019, Volume: 29, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate	2019
Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecologic oncology, 2019, Volume: 153, Issue:3 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; DNA Polymerase II; Endometrial Neoplasms; Female; Humans; Middle Aged; Mutation; Omentum; Paclitaxel; Pancreatic Neoplasms; Poly-ADP-Ribose Binding Proteins; Stomach Neoplasms	2019
Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecologic oncology, 2019, Volume: 154, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Treatment Outcome	2019
External Beam, Brachytherapy, or Chemotherapy? Defining Adjuvant Therapy for Early-Stage and High- and High-Intermediate-Risk Endometrial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 07-20, Volume: 37, Issue:21 Topics: Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Paclitaxel	2019
Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies). International journal of molecular sciences, 2019, Jul-31, Volume: 20, Issue:15 Topics: Aged; Antibodies, Neutralizing; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma; Carcinoma, Endometrioid; Cisplatin; DNA Mismatch Repair; Doxorubicin; Endometrial Neoplasms; Female; Gene Expression; Humans; Immunophenotyping; Lymphocytes, Tumor-Infiltrating; Microsatellite Instability; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Programmed Cell Death 1 Receptor	2019
Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials, 2013, Volume: 34, Issue:16 Topics: Cell Death; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Microscopy, Fluorescence; Nanoparticles; Ovarian Neoplasms; Oxazines; Paclitaxel; Particle Size; Polyesters; Spectroscopy, Fourier Transform Infrared; Static Electricity; Time Factors; Tumor Cells, Cultured; Water	2013
Comparison of "sandwich chemo-radiotherapy" and six cycles of chemotherapy followed by adjuvant radiotherapy in patients with stage IIIC endometrial cancer: a single center experience. Archives of gynecology and obstetrics, 2013, Volume: 288, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Retrospective Studies; Salpingectomy; Treatment Outcome	2013
Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers. International journal of cancer, 2013, Volume: 133, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bayes Theorem; Biomarkers, Tumor; Blotting, Western; Carboplatin; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Survival Rate; Tumor Cells, Cultured; Vidarabine	2013
Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Time Factors	2013
Concomitant paclitaxel plus carboplatin and radiotherapy for high-risk or advanced endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; China; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies	2013
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphatidylcholines; Polyethylene Glycols; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate	2013
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan	2013
Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin. Biomedical research (Tokyo, Japan), 2013, Volume: 34, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma; Cation Transport Proteins; Chemotherapy, Adjuvant; Copper Transporter 1; Endometrial Neoplasms; Female; Gene Expression; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Organic Anion Transporters, Sodium-Independent; Paclitaxel; Prognosis; Solute Carrier Organic Anion Transporter Family Member 1B3; Survival Analysis; Treatment Outcome	2013
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer. Gynecologic oncology, 2013, Volume: 130, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate	2013
Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer. International journal of molecular sciences, 2013, Aug-12, Volume: 14, Issue:8 Topics: Adjuvants, Immunologic; Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endometrial Neoplasms; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium Chloride; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Transplantation; Paclitaxel; Signal Transduction; Thiazoles; Urea; Xenograft Model Antitumor Assays	2013
Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclophilin A; Down-Regulation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; RNA Interference; RNA, Small Interfering	2013
The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecologic oncology, 2013, Volume: 131, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Risk Factors; Survival Rate	2013
Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecologic oncology, 2013, Volume: 131, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cohort Studies; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies	2013
Overcoming paclitaxel resistance in uterine endometrial cancer using a COX-2 inhibitor. Oncology reports, 2013, Volume: 30, Issue:6 Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etodolac; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; RNA, Messenger	2013
Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes. Radiation oncology (London, England), 2013, Oct-14, Volume: 8 Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Radiotherapy; Retrospective Studies	2013
Administration of concurrent vaginal brachytherapy during chemotherapy for treatment of endometrial cancer. International journal of radiation oncology, biology, physics, 2013, Nov-15, Volume: 87, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brachytherapy; Carboplatin; Chemoradiotherapy; Endometrial Neoplasms; Female; Genitalia; Humans; Hysterectomy; Intestine, Small; Middle Aged; Organs at Risk; Paclitaxel; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Rectum; Retrospective Studies; Time Factors; Urinary Bladder	2013
[Study of claudin-4 in the diagnosis and treatment of endometrial carcinoma]. Zhonghua fu chan ke za zhi, 2013, Volume: 48, Issue:10 Topics: Animals; Cell Line, Tumor; Cisplatin; Claudin-4; Disease Models, Animal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous	2013
Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate	2013
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecologic oncology, 2014, Volume: 133, Issue:2 Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Class I Phosphatidylinositol 3-Kinases; Endometrial Neoplasms; Female; Humans; Mice; Mice, SCID; Morpholines; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2014
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer. PloS one, 2014, Volume: 9, Issue:2 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bridged-Ring Compounds; Cell Line, Tumor; Endometrial Neoplasms; Female; Gene Knockdown Techniques; Humans; Neoplasm Metastasis; Paclitaxel; Stathmin; Taxoids; Treatment Outcome	2014
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Suppressor Protein p53	2014
Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer. Gynecologic oncology, 2014, Volume: 134, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Intensity-Modulated; Retrospective Studies	2014
Fat composition changes in bone marrow during chemotherapy and radiation therapy. International journal of radiation oncology, biology, physics, 2014, Sep-01, Volume: 90, Issue:1 Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Capecitabine; Cervical Vertebrae; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Fluorouracil; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Spine; Thoracic Vertebrae; Uterine Cervical Neoplasms	2014
Spontaneous pneumothorax after intensive chemotherapy in endometrial cancer: a rare complication. Taiwanese journal of obstetrics & gynecology, 2014, Volume: 53, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Lung Neoplasms; Paclitaxel; Pneumothorax; Remission Induction	2014
Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:15 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate	2014
Prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy followed by platinum-based chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Ifosfamide; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Para-Aortic Bodies; Pelvic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2015
Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Failure	2015
Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer. International journal of oncology, 2015, Volume: 46, Issue:4 Topics: Animals; Antineoplastic Agents, Phytogenic; Aurora Kinase A; Cell Line, Tumor; Disease-Free Survival; Endometrial Neoplasms; Female; Gene Knockdown Techniques; Humans; Mice; Paclitaxel; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays	2015
Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma. Gynecologic oncology, 2015, Volume: 137, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Cisplatin; Disease Progression; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome	2015
Autophagy inhibition enhances sensitivity of endometrial carcinoma cells to paclitaxel. International journal of oncology, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Chloroquine; Drug Synergism; Endometrial Neoplasms; Female; Humans; Membrane Proteins; Microtubule-Associated Proteins; Paclitaxel; RNA-Binding Proteins; Tubulin Modulators	2015
Loss of AF-6/afadin induces cell invasion, suppresses the formation of glandular structures and might be a predictive marker of resistance to chemotherapy in endometrial cancer. BMC cancer, 2015, Apr-12, Volume: 15 Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kinesins; MAP Kinase Signaling System; Middle Aged; Myosins; Neoplasm Invasiveness; Paclitaxel	2015
What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Taxoids	2015
Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer: A Pilot Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pilot Projects; Prognosis; Prospective Studies; Young Adult	2015
Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma. American journal of clinical oncology, 2017, Volume: 40, Issue:6 Topics: Abdominal Neoplasms; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Endometrioid; Carcinosarcoma; Chemoradiotherapy; Cohort Studies; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pelvic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Survival Rate; Tumor Burden	2017
MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:6 Topics: 3' Untranslated Regions; Antineoplastic Agents, Phytogenic; Autophagy; Binding Sites; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; MicroRNAs; Paclitaxel; Signal Transduction; Transfection; Up-Regulation	2015
Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Young Adult	2015
Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:2 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Retrospective Studies	2016
Singapore Cancer Network (SCAN) Guidelines for the Systemic Therapy of Endometrial (Uterine) Cancer. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Progestins; Singapore; Sirolimus; Tamoxifen	2015
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Combinations; Endometrial Neoplasms; Female; Gastrectomy; Humans; Hysterectomy; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur	2015
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate	2016
Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:3 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Remission Induction; Survival Rate	2016
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience. European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult	2016
Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy? European journal of gynaecological oncology, 2016, Volume: 37, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Salpingectomy	2016
Targeted Silencing of S100A8 Gene by miR-24 to Increase Chemotherapy Sensitivity of Endometrial Carcinoma Cells to Paclitaxel. Medical science monitor : international medical journal of experimental and clinical research, 2016, Jun-09, Volume: 22 Topics: 3' Untranslated Regions; Adult; Antineoplastic Agents, Phytogenic; Calgranulin A; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Endometrial Neoplasms; Female; Gene Silencing; Genetic Therapy; HEK293 Cells; Humans; MicroRNAs; Middle Aged; Paclitaxel; Transfection; Up-Regulation	2016
[Radiotherapy of cervix and endometrial carcinoma]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymphatic Irradiation; Lymphatic Metastasis; Organoplatinum Compounds; Organs at Risk; Paclitaxel; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided; Uterine Cervical Neoplasms	2016
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines. Endocrine, 2017, Volume: 56, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Human Growth Hormone; Humans; Nuclear Export Signals; Paclitaxel; Receptors, Somatotropin	2017
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells. International journal of oncology, 2016, Volume: 49, Issue:5 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured	2016
Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. Anticancer research, 2016, Volume: 36, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Trastuzumab	2016
Effective Selection of a Well-Differentiated Type of Human Uterine Endometrial Carcinoma Cells by Transfection of the Sulfotransferase Gene and Possible Association of Sulfoglycolipids With Well-Differentiated Phenotypes. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:2 Topics: Animals; Cattle; Cell Differentiation; Cell Line, Tumor; Endometrial Neoplasms; Female; Glycolipids; Humans; Paclitaxel; Phenotype; Rats; Sulfotransferases; Transfection	2017
Cell-like features imprinted in the physical nano- and micro-topography of the environment modify the responses to anti-cancer drugs of endometrial cancer cells. Biofabrication, 2017, Feb-14, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Bioprinting; Caspase 3; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Microscopy, Electron, Scanning; Nanostructures; Paclitaxel; Polystyrenes; Proliferating Cell Nuclear Antigen; Surface Properties; Vascular Endothelial Growth Factor A	2017
Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cohort Studies; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies	2017
Autocrine Prolactin Stimulates Endometrial Carcinoma Growth and Metastasis and Reduces Sensitivity to Chemotherapy. Endocrinology, 2017, 06-01, Volume: 158, Issue:6 Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Endometrioid; Cell Proliferation; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Prolactin; Tumor Cells, Cultured	2017
Long non-coding RNA LINC00672 contributes to p53 protein-mediated gene suppression and promotes endometrial cancer chemosensitivity. The Journal of biological chemistry, 2017, 04-07, Volume: 292, Issue:14 Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Animals; Cytoskeletal Proteins; Down-Regulation; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; LIM Domain Proteins; Mice; Mice, Knockout; Middle Aged; Neoplasm Transplantation; Paclitaxel; RNA, Long Noncoding; RNA, Neoplasm; Tumor Suppressor Protein p53	2017
Safety of herbal medicine use during chemotherapy in patients with ovarian cancer: a "bedside-to-bench" approach. Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; HEK293 Cells; Herb-Drug Interactions; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Plant Preparations; Uterine Cervical Neoplasms	2017
[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells]. Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:8 Topics: Acetylation; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 9; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Synergism; Endometrial Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Potential, Mitochondrial; Microtubules; Paclitaxel; Poly(ADP-ribose) Polymerases; Tubulin	2008
A case of oncocytic carcinoma of the endometrium. Archives of gynecology and obstetrics, 2009, Volume: 279, Issue:5 Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Neoplasms, Second Primary; Paclitaxel	2009
Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience. Gynecologic oncology, 2008, Volume: 111, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Papillary; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Paclitaxel; Retrospective Studies; Risk Factors	2008
Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-15, Volume: 14, Issue:22 Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Chromatography, High Pressure Liquid; Disease Progression; Endometrial Neoplasms; Enzyme Inhibitors; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Killer Cells, Natural; Mice; Mice, Nude; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Xenograft Model Antitumor Assays	2008
[Combination chemotherapy with paclitaxel and carboplatin (TC therapy) for endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel	2008
Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecologic oncology, 2009, Volume: 112, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Radiotherapy; Vagina	2009
[Effects of trichostatin A and paclitaxel on apoptosis and microtubule stabilization in endometrial carcinoma cells: an in vitro research]. Zhonghua yi xue za zhi, 2008, Sep-09, Volume: 88, Issue:34 Topics: Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Hydroxamic Acids; Microtubule Proteins; Microtubules; Paclitaxel	2008
Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecologic oncology, 2009, Volume: 114, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel	2009
Topotecan-induced long-term remission of an advanced endometrial cancer after treatment with cisplatinum, an anthracycline and paclitaxel. Anticancer research, 2009, Volume: 29, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Remission Induction; Topotecan	2009
Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:4 Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies	2009
Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? British journal of cancer, 2009, Jul-21, Volume: 101, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prospective Studies	2009
Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Inhibitory Concentration 50; Middle Aged; Ovarian Neoplasms; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome	2009
The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:5 Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome	2009
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. Gynecologic oncology, 2009, Volume: 115, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Radiotherapy, Adjuvant; Treatment Outcome	2009
Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. International journal of cancer, 2010, Mar-01, Volume: 126, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Paclitaxel; Protein Kinases; Signal Transduction; Sirolimus; Telomerase; TOR Serine-Threonine Kinases; Tubulin	2010
Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells. European journal of gynaecological oncology, 2009, Volume: 30, Issue:3 Topics: 2-Methoxyestradiol; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Estradiol; Female; Humans; Paclitaxel; Tumor Cells, Cultured	2009
Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group. Gynecologic oncology, 2009, Volume: 115, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Japan; Neoplasm Staging; Paclitaxel; Postoperative Care; Practice Patterns, Physicians'	2009
PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells. International journal of molecular medicine, 2010, Volume: 25, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Cisplatin; Endometrial Neoplasms; Endometrium; Epithelial Cells; Female; Humans; Isoquinolines; Membrane Potential, Mitochondrial; Ovarian Neoplasms; Paclitaxel	2010
Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2010, Volume: 109, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Tumor Lysis Syndrome	2010
A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma. International journal of clinical oncology, 2010, Volume: 15, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Hysterectomy; Japan; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Retrospective Studies; Time Factors; Treatment Outcome	2010
High levels of Nrf2 determine chemoresistance in type II endometrial cancer. Cancer research, 2010, Jul-01, Volume: 70, Issue:13 Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Carcinoma, Endometrioid; Cell Growth Processes; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Mice; Mice, SCID; Middle Aged; NF-E2-Related Factor 2; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays	2010
Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Epirubicin; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome	2011
Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Databases, Factual; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Statistics, Nonparametric; Treatment Outcome	2010
Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer. British journal of cancer, 2010, Sep-07, Volume: 103, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Blotting, Western; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization; Middle Aged; Paclitaxel; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Survival Analysis	2010
Advanced age is a significant determinant of poor prognosis in patients treated with surgery plus postoperative radiotherapy for endometrial cancer. The journal of obstetrics and gynaecology research, 2010, Volume: 36, Issue:4 Topics: Age Factors; Aged; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Treatment Outcome	2010
Amifostine enhancement of the anti-cancer effects of paclitaxel in endometrial cancer is TP53-dependent. International journal of oncology, 2010, Volume: 37, Issue:5 Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Synergism; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Mice; Mice, Nude; Mutation; Paclitaxel; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2010
CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer. Gynecologic oncology, 2011, Volume: 120, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Endometrioid; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Treatment Outcome	2011
Impact of platinum-based chemotherapy on the progression of atherosclerosis. Climacteric : the journal of the International Menopause Society, 2011, Volume: 14, Issue:1 Topics: Ankle Brachial Index; Antineoplastic Agents; Atherosclerosis; Blood Flow Velocity; Brachial Artery; Calcimycin; Carboplatin; Cells, Cultured; Chemotherapy, Adjuvant; Cisplatin; Endometrial Neoplasms; Endothelial Cells; Endothelium, Vascular; Female; Humans; Ionophores; Middle Aged; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Triglycerides; Ultrasonography; Umbilical Veins	2011
[Regulation of Bub1 mRNA expression in endometrial carcinoma Ishikawa cells by estrogen and paclitaxel]. Zhonghua fu chan ke za zhi, 2010, Volume: 45, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors	2010
Pyomyositis after chemotherapy for endometrial cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7 Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drainage; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Pyomyositis; Treatment Outcome	2010
Consistency of in vitro chemoresponse assay results and population clinical response rates among women with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:3 Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Survival; Cisplatin; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Female; Humans; In Vitro Techniques; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; United States	2011
Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma. Bioorganic & medicinal chemistry, 2011, Jul-01, Volume: 19, Issue:13 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Endometrial Neoplasms; Female; Folic Acid; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Transplantation, Heterologous	2011
Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings. Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:2 Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Paclitaxel; Predictive Value of Tests; Preoperative Care; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Salpingectomy	2012
CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DNA Primers; Endometrial Neoplasms; Female; Gene Silencing; Humans; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Polymerase Chain Reaction; RNA, Messenger; Ubiquitin-Protein Ligases	2011
Expression of ERCC1, p53, and class III β-tubulin do not reveal chemoresistance in endometrial cancer: results from an immunohistochemical study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endometrial Neoplasms; Endonucleases; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tubulin; Tumor Suppressor Protein p53	2011
The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Journal of surgical oncology, 2012, Volume: 105, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Omentum; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Retrospective Studies; Survival Rate; Treatment Outcome	2012
Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer. Gynecologic oncology, 2012, Volume: 124, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Membrane Proteins; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Predictive Value of Tests	2012
Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma. Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:5 Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Paclitaxel; Recurrence; Remission Induction; Retrospective Studies	2012
[Results of chemotherapy for gynecologic cancer patients in ambulatory care]. Voprosy onkologii, 2011, Volume: 57, Issue:4 Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms	2011
Effects of female sex hormones on clusterin expression and paclitaxel resistance in endometrial cancer cell lines. International journal of medical sciences, 2012, Volume: 9, Issue:1 Topics: Cell Line, Tumor; Clusterin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Paclitaxel; Progesterone; Receptors, Progesterone; RNA, Small Interfering	2012
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. Gynecologic oncology, 2012, Volume: 125, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Flow Cytometry; Humans; Metformin; Paclitaxel; RNA, Messenger; Signal Transduction; Telomerase; TOR Serine-Threonine Kinases	2012
Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells. Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2011
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:4 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate	2012
RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells. Oncology reports, 2012, Volume: 28, Issue:1 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B1; Endometrial Neoplasms; Female; Gene Expression; Gene Knockdown Techniques; Humans; Mitosis; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; RNA Interference; Ubiquitin-Protein Ligases	2012
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. The journal of obstetrics and gynaecology research, 2012, Volume: 38, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Evaluation, Preclinical; Drug Synergism; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoglycemic Agents; Lactoylglutathione Lyase; Metformin; Paclitaxel	2012
GRP78 induced by estrogen plays a role in the chemosensitivity of endometrial cancer. Gynecologic oncology, 2012, Volume: 126, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cisplatin; Endometrial Neoplasms; Endoplasmic Reticulum Chaperone BiP; Estradiol; Estrogen Receptor alpha; Female; Heat-Shock Proteins; Humans; Paclitaxel; RNA, Messenger; RNA, Small Interfering; Transfection	2012
Feasibility study of paclitaxel plus carboplatin in patients with endometrial cancer: a Japan Kanto Tumor Board study (JKTB trial). The journal of obstetrics and gynaecology research, 2013, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Longitudinal Studies; Middle Aged; Paclitaxel; Treatment Outcome	2013
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecologic oncology, 2012, Volume: 127, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Administration Schedule; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Retrospective Studies; Salpingectomy; Survival Analysis; Treatment Outcome	2012
Abandoning "TAP" as treatment of metastatic endometrial cancer: a serious example of the consequences resulting from the failure to adequately define the question being addressed in a phase 3 trial. Current oncology reports, 2012, Volume: 14, Issue:6 Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase III as Topic; Doxorubicin; Endometrial Neoplasms; Female; Humans; Neoplasm Metastasis; Paclitaxel	2012
Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. International journal of oncology, 2012, Volume: 41, Issue:5 Topics: Adenocarcinoma; Antigens, Surface; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Karyotype; Paclitaxel	2012
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:8 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate	2012
Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Endometrioid; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Female; Humans; Mutation; Paclitaxel; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Tumor Cells, Cultured	2012
Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo. Oncology reports, 2013, Volume: 29, Issue:1 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Papillary; Carcinoma, Transitional Cell; Cell Proliferation; Cofilin 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Vitro Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Up-Regulation	2013
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53. Gynecologic oncology, 2013, Volume: 128, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Mitosis; Paclitaxel; Pteridines; Quinazolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2013
Comparison of outcomes in patients treated with multi-agent regiments of cisplatin, adriamycin, and VP-16 versus carboplatin and paclitaxel for advanced and recurrent endometrial cancer. European journal of gynaecological oncology, 2012, Volume: 33, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2012
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Oncology, 2013, Volume: 84, Issue:3 Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate	2013
Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin. International journal of clinical oncology, 2002, Volume: 7, Issue:3 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Endometrioid; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Japan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Radiography, Thoracic; Remission Induction; Time Factors; Tomography, X-Ray Computed; Uterine Hemorrhage	2002
The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer detection and prevention, 2003, Volume: 27, Issue:1 Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Neoplasm Staging; Paclitaxel; Retrospective Studies; Tetrazolium Salts; Topotecan; Toxicity Tests; Treatment Outcome; Uterine Cervical Neoplasms	2003
Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study. International journal of clinical oncology, 2003, Volume: 8, Issue:1 Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Disease Progression; Drug Evaluation; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pleurodynia, Epidemic; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome; Women's Health	2003
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer. International journal of clinical oncology, 2003, Volume: 8, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Tomography, X-Ray Computed	2003
[Paclitaxel and carboplatin with or without pirarubicin (THP-ADR) as first line chemotherapy in elderly patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms	2003
[A case of uterine endometrial cancer with lung metastases improved by various treatments including taxane]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Paclitaxel; Taxoids	2003
Malignant acanthosis nigricans and endometrioid adenocarcinoma of the parametrium: the search for malignancy. Journal of the American Academy of Dermatology, 2003, Volume: 49, Issue:3 Topics: Acanthosis Nigricans; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Paclitaxel; Risk Assessment; Treatment Outcome	2003
Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis. Anti-cancer drugs, 2003, Volume: 14, Issue:9 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Renal Dialysis; Renal Insufficiency; Time Factors	2003
Successful treatment with weekly paclitaxel in a patient with recurrent endometrial cancer. A case report. European journal of gynaecological oncology, 2003, Volume: 24, Issue:5 Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Paclitaxel; Ultrasonography	2003
Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecologic oncology, 2004, Volume: 92, Issue:1 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Paclitaxel	2004
Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anti-cancer drugs, 2004, Volume: 15, Issue:1 Topics: Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Endometrial Neoplasms; Enzyme Inhibitors; Female; Humans; Ovarian Neoplasms; Paclitaxel; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction	2004
[A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Paclitaxel; Pilot Projects; Thrombocytopenia	2004
[Successful treatment of endometrial carcinoma associated with lung metastasis by paclitaxel and carboplatin chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Hysterectomy; Lung Neoplasms; Lymph Node Excision; Paclitaxel; Pelvis; Postoperative Care; Prognosis	2004
Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma. Gynecologic oncology, 2004, Volume: 95, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Endometrioid; Cell Line, Tumor; Cisplatin; Cystinyl Aminopeptidase; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Transfection	2004
Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. American journal of obstetrics and gynecology, 2005, Volume: 192, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome	2005
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Treatment Outcome	2005
Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report. Gynecologic oncology, 2006, Volume: 100, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Endometrial Neoplasms; Epirubicin; Female; Humans; Paclitaxel; Pamidronate	2006
A novel role for placental leucine aminopeptidase (P-LAP) as a determinant of chemoresistance in endometrial carcinoma cells. International journal of cancer, 2006, Mar-15, Volume: 118, Issue:6 Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carboplatin; Caspases; Cell Line, Tumor; Cystinyl Aminopeptidase; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Activation; Female; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transfection	2006
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. International journal of radiation oncology, biology, physics, 2005, Nov-01, Volume: 63, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Regression Analysis; Survival Rate	2005
[Antitumor effect of docetaxel against human endometrial tumor cell lines]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10 Topics: Animals; Antineoplastic Agents, Phytogenic; Cisplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Tumor Cells, Cultured	2005
A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. Cancer research, 2005, Oct-15, Volume: 65, Issue:20 Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Mice; Mice, Nude; Paclitaxel; Proto-Oncogene Proteins c-jun; Xenograft Model Antitumor Assays	2005
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. European journal of gynaecological oncology, 2005, Volume: 26, Issue:6 Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome	2005
Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecologic oncology, 2006, Volume: 103, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Retrospective Studies; Treatment Outcome	2006
Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. The journal of obstetrics and gynaecology research, 2006, Volume: 32, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Retrospective Studies	2006
Peripheral arterial thrombosis induced by chemotherapy in ovarian carcinoma coexisted with endometrial carcinoma. Archives of gynecology and obstetrics, 2007, Volume: 275, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Vascular Diseases; Postmenopause; Thrombocytopenia; Thrombosis	2007
Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma. Gynecologic oncology, 2007, Volume: 104, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel	2007
Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. International journal of radiation oncology, biology, physics, 2007, Jan-01, Volume: 67, Issue:1 Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Drug Administration Schedule; Endometrial Neoplasms; Feasibility Studies; Female; Humans; Hysterectomy; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy Dosage	2007
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Molecular cancer therapeutics, 2006, Volume: 5, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 9; Drug Synergism; Endometrial Neoplasms; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Mice; Mice, Nude; Microtubules; Paclitaxel; Tumor Cells, Cultured	2006
Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncology reports, 2007, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Decitabine; DNA Methylation; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Proteins; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Taxoids; Ubiquitin-Protein Ligases	2007
Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:4 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome	2006
[A case of advanced clear cell carcinoma of the endometrium that responded remarkably to neoadjuvant chemotherapy of combination carboplatin plus weekly paclitaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3 Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Hysterotomy; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Remission Induction	2007
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. International journal of clinical oncology, 2007, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinosarcoma; Disease-Free Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; North Carolina; Paclitaxel; Pilot Projects; Treatment Outcome; Utah; Uterine Cervical Neoplasms	2007
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Cisplatin; Doxorubicin; Endometrial Neoplasms; Female; Gene Amplification; Genes, erbB-2; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2	2008
Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. Radiation medicine, 2007, Volume: 25, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Treatment Outcome	2007
Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report. Archives of gynecology and obstetrics, 2008, Volume: 278, Issue:3 Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms	2008
Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecologic oncology, 2008, Volume: 108, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Cycle; Cell Line, Tumor; Ellipticines; Endometrial Neoplasms; Female; Flow Cytometry; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Paclitaxel; Proto-Oncogene Proteins c-akt; Signal Transduction	2008
Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecologic oncology, 2008, Volume: 109, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome	2008
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:12 Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ovarian Neoplasms; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis; Tumor Cells, Cultured	2008
Extra-pelvic metastasis of endometrioid carcinoma; resistance to chemo-radiation therapy--response to paclitaxel treatment. Case report. European journal of gynaecological oncology, 1995, Volume: 16, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Ovarian Neoplasms; Paclitaxel	1995
Taxol is active in platinum-resistant endometrial adenocarcinoma. American journal of clinical oncology, 1996, Volume: 19, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Cisplatin; Drug Resistance; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel	1996
Paclitaxel: current developmental approaches of the National Cancer Institute. Seminars in oncology, 1995, Volume: 22, Issue:6 Suppl 15 Topics: AIDS-Related Opportunistic Infections; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Administration Schedule; Endometrial Neoplasms; Esophageal Neoplasms; Female; Germinoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Ovarian Neoplasms; Paclitaxel; Sarcoma, Kaposi; United States; Urinary Bladder Neoplasms	1995
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience. Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 15 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome	1997
[Evaluation of a new anti-cancer drug regimen for endometrial cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Irinotecan; Lethal Dose 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel	1998
Prolonged remission of endometrial cancer with paclitaxel and carboplatin. Anti-cancer drugs, 1998, Volume: 9, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Recurrence; Time Factors	1998
Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields. Gynecologic oncology, 1998, Volume: 71, Issue:1 Topics: Cell Division; Cisplatin; Electromagnetic Fields; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Male; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured	1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured	1997
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer. Gynecologic oncology, 1999, Volume: 73, Issue:3 Topics: Adenocarcinoma; Endometrial Neoplasms; Female; Humans; Middle Aged; Paclitaxel; Platinum; Remission Induction	1999
The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma. European journal of gynaecological oncology, 1999, Volume: 20, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Papillary; Endometrial Neoplasms; Female; Humans; Megestrol Acetate; Paclitaxel; Prognosis; Treatment Outcome	1999
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer. Journal of hematotherapy & stem cell research, 2000, Volume: 9, Issue:2 Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids	2000
Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anti-cancer drugs, 2000, Volume: 11, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Neoplasm Staging; Paclitaxel; Recombinant Proteins; Sarcoma, Endometrial Stromal; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Conditioning; Tuberculosis, Pulmonary	2000
Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecologic oncology, 2000, Volume: 78, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Paclitaxel; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Surgical Procedures, Operative; Survival Analysis; Time Factors	2000
In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs. Anti-cancer drugs, 2000, Volume: 11, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Irinotecan; Paclitaxel; Tumor Cells, Cultured	2000
Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel. Cancer letters, 2000, Nov-10, Volume: 160, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Endometrial Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Treatment Outcome	2000
Endometrial adenocarcinoma arising during estrogenic treatment 17 years after total abdominal hysterectomy and bilateral salpingo-oophorectomy: a case report. Acta obstetricia et gynecologica Scandinavica, 2001, Volume: 80, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Transformation, Neoplastic; Colonic Neoplasms; Endometrial Neoplasms; Endometriosis; Estrogen Replacement Therapy; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Ovariectomy; Paclitaxel	2001
Resistance to topoisomerase poisons due to loss of DNA mismatch repair. International journal of cancer, 2001, Aug-15, Volume: 93, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2001
Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. Acta obstetricia et gynecologica Scandinavica, 2001, Volume: 80, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clostridioides difficile; Diarrhea; Endometrial Neoplasms; Enterocolitis, Pseudomembranous; Female; Humans; Middle Aged; Paclitaxel	2001